WO2020224960A1 - Hydrophilic nonwoven nanofibers membrane for promoting bone regeneration - Google Patents
Hydrophilic nonwoven nanofibers membrane for promoting bone regeneration Download PDFInfo
- Publication number
- WO2020224960A1 WO2020224960A1 PCT/EP2020/061184 EP2020061184W WO2020224960A1 WO 2020224960 A1 WO2020224960 A1 WO 2020224960A1 EP 2020061184 W EP2020061184 W EP 2020061184W WO 2020224960 A1 WO2020224960 A1 WO 2020224960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- hydrophilic nonwoven
- copolymer
- bone
- hea
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 197
- 239000002121 nanofiber Substances 0.000 title claims abstract description 68
- 230000010478 bone regeneration Effects 0.000 title claims abstract description 14
- 230000001737 promoting effect Effects 0.000 title claims abstract description 6
- 229920001577 copolymer Polymers 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000008569 process Effects 0.000 claims abstract description 45
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 230000003239 periodontal effect Effects 0.000 claims abstract description 11
- 150000001768 cations Chemical class 0.000 claims abstract description 10
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 9
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 63
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 41
- 229910052751 metal Inorganic materials 0.000 claims description 40
- 239000002184 metal Substances 0.000 claims description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 36
- 230000003197 catalytic effect Effects 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 238000001523 electrospinning Methods 0.000 claims description 25
- 229960003722 doxycycline Drugs 0.000 claims description 23
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 20
- 239000010949 copper Substances 0.000 claims description 19
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000007943 implant Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003999 initiator Substances 0.000 claims description 11
- 238000010526 radical polymerization reaction Methods 0.000 claims description 11
- 230000002441 reversible effect Effects 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 8
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 claims description 7
- 229910052723 transition metal Inorganic materials 0.000 claims description 7
- 150000003624 transition metals Chemical class 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- VMGSQCIDWAUGLQ-UHFFFAOYSA-N n',n'-bis[2-(dimethylamino)ethyl]-n,n-dimethylethane-1,2-diamine Chemical compound CN(C)CCN(CCN(C)C)CCN(C)C VMGSQCIDWAUGLQ-UHFFFAOYSA-N 0.000 claims description 5
- VFXXTYGQYWRHJP-UHFFFAOYSA-N 4,4'-azobis(4-cyanopentanoic acid) Chemical compound OC(=O)CCC(C)(C#N)N=NC(C)(CCC(O)=O)C#N VFXXTYGQYWRHJP-UHFFFAOYSA-N 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- -1 copper amine Chemical class 0.000 claims description 3
- 239000002608 ionic liquid Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- VGUWFGWZSVLROP-UHFFFAOYSA-N 1-pyridin-2-yl-n,n-bis(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 VGUWFGWZSVLROP-UHFFFAOYSA-N 0.000 claims description 2
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 claims description 2
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 claims description 2
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 claims description 2
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 claims description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 2
- 102100020870 La-related protein 6 Human genes 0.000 claims description 2
- 108050008265 La-related protein 6 Proteins 0.000 claims description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 claims description 2
- 101100490446 Penicillium chrysogenum PCBAB gene Proteins 0.000 claims description 2
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- VBWIZSYFQSOUFQ-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#CC1CCCCC1 VBWIZSYFQSOUFQ-UHFFFAOYSA-N 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- TUPZPNIRCIQNLF-UHFFFAOYSA-N dodecyl 2-bromo-2-methylpropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)(C)Br TUPZPNIRCIQNLF-UHFFFAOYSA-N 0.000 claims description 2
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 claims description 2
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- DWFKOMDBEKIATP-UHFFFAOYSA-N n'-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CCN(C)CCN(C)C DWFKOMDBEKIATP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- RBOQJHMBYJZWJL-UHFFFAOYSA-N octadecyl 2-bromo-2-methylpropanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(C)(C)Br RBOQJHMBYJZWJL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- RMWVUWLBLWBQDS-UHFFFAOYSA-N tert-butyl 3-bromopropanoate Chemical compound CC(C)(C)OC(=O)CCBr RMWVUWLBLWBQDS-UHFFFAOYSA-N 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 description 84
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 78
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 41
- 229910001424 calcium ion Inorganic materials 0.000 description 40
- 239000000243 solution Substances 0.000 description 35
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 25
- 230000007547 defect Effects 0.000 description 25
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 23
- 239000000835 fiber Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 19
- 235000012239 silicon dioxide Nutrition 0.000 description 19
- 239000000178 monomer Substances 0.000 description 16
- 239000011575 calcium Substances 0.000 description 15
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- 238000007334 copolymerization reaction Methods 0.000 description 14
- 210000000963 osteoblast Anatomy 0.000 description 13
- 230000011164 ossification Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000005299 abrasion Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000007669 thermal treatment Methods 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- 101710141544 Allatotropin-related peptide Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 230000003592 biomimetic effect Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000349 field-emission scanning electron micrograph Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- ACEONLNNWKIPTM-UHFFFAOYSA-N methyl 2-bromopropanoate Chemical compound COC(=O)C(C)Br ACEONLNNWKIPTM-UHFFFAOYSA-N 0.000 description 5
- 238000010883 osseointegration Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910001961 silver nitrate Inorganic materials 0.000 description 5
- 210000003625 skull Anatomy 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002159 nanocrystal Substances 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 3
- 241000186045 Actinomyces naeslundii Species 0.000 description 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000194025 Streptococcus oralis Species 0.000 description 3
- 241001148135 Veillonella parvula Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000000316 bone substitute Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 235000015246 common arrowhead Nutrition 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 210000005009 osteogenic cell Anatomy 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- VMAKIACTLSBBIY-BOPFTXTBSA-N (z)-3-(4-chloroanilino)-n-(4-chlorophenyl)-2-(3-methyl-1,2-oxazol-5-yl)prop-2-enamide Chemical compound O1N=C(C)C=C1C(\C(=O)NC=1C=CC(Cl)=CC=1)=C\NC1=CC=C(Cl)C=C1 VMAKIACTLSBBIY-BOPFTXTBSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 description 1
- 208000036632 Brain mass Diseases 0.000 description 1
- 241001286462 Caio Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241000023506 Porphyromonas gingivalis ATCC 33277 Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000124960 Turris Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
- A61K6/887—Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L31/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers
- C08L31/02—Homopolymers or copolymers of esters of monocarboxylic acids
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43838—Ultrafine fibres, e.g. microfibres
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/724—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged forming webs during fibre formation, e.g. flash-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the invention relates to a hydrophilic nonwoven nanofiber membrane based on acrylate and methacrylate copolymers and its process of preparation. Furthermore, the invention refers to its hydrolysed form further functionalised with a divalent cation selected from Zn +2 , Ca +2 , Mg +2 and Sr +2 , an antibacterial agent and any of the combinations thereof.
- the invention refers to a non-resorbable membrane for promoting bone regeneration and a non-resorbable periodontal membrane comprising said hydrophilic nonwoven nanofiber membrane, its hydrolysed form or its hydrolysed form further functionalised with a divalent cation selected from Zn +2 , Ca +2 , Mg +2 and Sr +2 , an antibacterial agent and any of the combinations thereof.
- GBR Guided Bone Regeneration
- resorbable tissue-engineered matrices to induce bone formation, when additional support is needed, is not always successful.
- a major limitation of resorbable materials is the inability to exert spatiotemporal control over the wound-healing process.
- Most of the employed resorbable membranes e.g. collagen, polylactide-co- glycolide, polycaprolactone
- bone graft substitutes e.g. hydroxyapatite -HAp- and other calcium phosphates
- employed resorbable materials may be disadvantageous, as dissolution behaviors are not as long-lasting as required.
- some degradation products from these resorbable materials have low pH, they may not be cytocompatible and could also alter the remineralization processes [Ivanovski S, Vaquette C, Gronthos S, Hutraum DW, Bartold PM (2014) Multiphasic Scaffolds for Periodontal Tissue Engineering. J Dent Res 93(12):1212-1221 ] [Shimauchi H, Nemoto E, Ishihata H, Shimomura M (2013) Possible functional scaffolds for periodontal regeneration. Japan Dent Sci Rev 49:1 18- 130].
- non-resorbable synthetic membranes of polytetrafluoroethylene still represent the gold-standard for clinicians, due to the higher predictability of their effects when compared to resorbable membranes.
- PTFE possess important disadvantages: I) low adhesiveness for cells, II) total absence of the capability of connecting to the bone tissue and providing osseointegration, without formation of a connective tissue interlayer; then a second surgery is required to remove the non- integrated membrane, and finally III) lack of antibacterial properties, being infections frequently observed [Sam G, Pillai BRM (2014) Evolution of Barrier Membranes in Periodontal Regeneration-Are the third Generation Membranes J of Clin Diagn Res 8: 14-17] Therefore, a successful membrane for GBR should resemble the morphology of natural bone.
- Natural bone is a hybrid of inorganic-organic tissue composed of hydroxyapatite nanocrystals and collagen fibers (with diameters ranging from 50 to 500nm) assembled into a porous mesh, with interconnected pores. Bone is nanostructured, so nanosized materials should be the best choice for bone substitutes.
- a first aspect of the present invention relates to a hydrophilic nonwoven nanofibers membrane (herein“the membrane of the invention”) characterised in that it comprises a blend of
- hydrophilic nonwoven nanofibers membrane refers to a membrane formed by long fibers having a diameter of between 150nm and 400nm. Said membranes are nonwoven, this means that they are like a felt, which are neither woven nor knitted: they are made from long fibers (continuous long), bonded together by chemical, mechanical, heat or solvent treatment, and have a hydrophilic character.
- each needle produces a single fiber that is wound on the drum from the beginning to the end of the electrospinning process (kilometric).
- the reality is that fibers are cut intermittently along the electrospinning process.
- copolymer with statistical topology refers to statistical copolymers, that is to say, a copolymer in which the distribution of the monomers in the chain is random since all the monomers present in the solution have the same affinity/probability to react both with monomers of the same chemical nature (with themselves) and with monomers of a different chemical nature.
- Said membrane exhibits abrasion resistance, flexibility, elasticity, stress resistance, and thus it can be easily manipulated: can be cut, bend and twist.
- One of the most important parameter in the electrospinning process is the molecular weight of the polymer. Higher molecular weight is generally preferred as there will be greater chains entanglement which facilitates the formation of fibers during spinning. In contrast, lower molecular weight may break up into droplets forming beads or beads combined with short fibers, resulting in heterogeneous materials with unwanted physical properties: irregular surface, low specific surface, low resistance to abrasion, and stress, loss of elasticity.
- the first copolymer of (MA) 3 -CO-(HEA) 2 has molecular weight between 50000 Da and 3-10 6 Da, preferably above 80000 Da. More preferably, the first copolymer of (MA) 3 -co-(HEA) 2 has molecular weight between 1 10 6 Da and 3- 10 6 Da.
- the second copolymer of (MMA)i-co-(HEMA)i has molecular weight between 50000 Da and 1 10 6 Da.
- the membrane further comprises Si0 2 nanoparticles (NPs-Si0 2 ), and said Si0 2 nanoparticles are
- Silicon dioxide (Si0 2 ) is able to improve not only bioactivity of materials but also cell adhesion and proliferation on artificial tissues, facilitating osteogenic cells differentiation.
- Si0 2 is considered to be osteoinductive and a catalyst for bone formation. Therefore, in order to improve the bioactivity of membranes they were doped with Si0 2 nanoparticles.
- the Si0 2 nanoparticles can be introduced in the membranes by two ways: 1 ) suspending them in the electrospinning solution, and then carry out the electrospinning process. In this case the NPs-Si0 2 are trapped homogeneously into the whole fiber volume, forming a solid solution (composite); 2) by physical adsorption in the surface of the fibers once the membrane is made: the membrane is soaked with a suspension of NPS-S1O2, and then the water is evaporated.
- the option (1 ) is preferred because NPs-SiC>2 are retained in the fibers more efficiently and its leaching is minimized; by (1 ) the NPs- S1O2 can remain in the membrane for longer times than by (2).
- a second aspect of the present invention relates to a process of preparation of the membrane of the present invention (herein“the process of the invention”) that includes the preparation of the copolymers which are electrospun to produce said membrane.
- the copolymers of the present invention can be prepared by Conventional Free- Radical Polymerization or by Metal-Catalysed Living Radical Polymerization (MC-LRP) such as normal Atom Transfer Radical Polymerization (Normal ATRP), reverse Atom Transfer Radical Polymerization (reverse ATRP) and activator generated by electron transfer atom transfer radical polymerization (AGET ATRP).
- the process is characterised in that it comprises the following steps:
- step (c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning, and
- step (c) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30 e C and 80 e C, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
- Step (a) of the process of the invention refers herein to the synthesis of the first copolymer of (MA) 3 -co-(HEA) 2 by Metal-Catalysed Living Radical Polymerization using a metal catalytic system and step (b) refers to the synthesis of the second copolymer of (MMA)i-co-(HEMA)i by Reverse Atom Transfer Radical Polymerization using a metal catalytic system.
- Method “Metal-catalysed living radical polymerization” refers to polymerization methods based on establishing a rapid dynamic equilibration between a minute amount of growing free radicals and a large majority of the dormant species, in which a low oxidation state metal complex acts as the catalyst.
- Reverse Atom Transfer Radical Polymerization refers to the polymerization methods based on establishing a rapid dynamic equilibration between a minute amount of growing free radicals and a large majority of the dormant species, in which a low oxidation state metal complex acts as the catalyst, the dormant species are alkyl halides, and the reaction is initiated by a conventional radical initiator and a Cu" complex.
- the term“metal catalytic system” refers to the catalyst used in the Metal-Catalysed Living Radical Polymerization of step (a) and to the catalyst used in the reverse Atom Transfer Radical Polymerization of step (b).
- Said metal catalytic system comprises a metal, a ligand and an initiator and uses a particular solvent.
- the metal catalytic system of step (a) and step (b) is a copper amine complex.
- the metal of the metal catalytic system of step (a) and/or step (b) comprises a transition metal or a mixture of transition metals in different oxidation states. More preferably, the metal of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of Cu, Fe, Co, Ni, Ru, PI, Rh, Re, Cr and Mo.
- said metal of the metal catalytic system of step (a) and/or step (b) is in a weight percentage comprised between 0.00001 % and 0.1 %.
- the ligand of the metal catalytic system of step (a) and/or step (b) is a multidentate aliphatic amine which can be linear or branched. More preferably, the ligand of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of N,N,N',N",N"-Pentamethyldiethylenetriamine (PMDETA) Tris(2-pyridylmethyl)amine, Tris[2-(dimethylamino)ethyl]amine, 2,2'-Bipyridyl, N,N,N',N'- Tetrakis(2-pyridylmethyl)ethylenediamine and 1 ,1 ,4,7,10,10- Hexamethyltriethylenetetramine.
- said ligand is in a weight percentage between 0.0001 % and 0.2%.
- step (a) and step (b) are preferably different.
- the initiator of the metal catalytic system of step (a) is independently selected from the list consisting of Dodecyl 2-bromoisobutyrate, Ethyl a- bromoisobutyrate, Ethyl a-bromoisobutyrate, Octadecyl 2-bromoisobutyrate, Methyl a- bromoisobutyrate, Methyl 3-bromopropionate, tert-Butyl 3-bromopropionate, Ethyl 2- bromopropionate.
- the initiator of step (b) is independently selected from the list consisting of 1 ,Tazobis(cyclohexanecarbonitrile) (ACHN), 2,2’-azobis (2-methylpropionamidine) 2,2’- dihydrochloride (AAPH), 4,4’-azobis(4-cyanovaleric acid) (ACVA), tert-butyl hydroperoxide, cumene hydroperoxide, 2,5-di(tert-butylperoxide)-2,5-dimethyl-3- hexyne, dicumyl peroxide and 2,5-bis(tert-butylperoxide)-2,5-dimethylhexane.
- ACVA 4,4’-azobis(4-cyanovaleric acid)
- the weight percentage of the initiator in step (a) and step (b) is between 0.00001 % and 0.2%.
- the solvent used with the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of acetone, dimethyl formamide, polyethylene glycol), dimethyl sulfoxide, 1 -4 Dioxane, ethanol, propanol, hexane, water, carbon dioxide , ionic liquid, and a combination thereof.
- the weight percentage of the solvent in step (a) and step (b) is below 90%; preferably the weight percentage of the solvent in step (a) and step (b) is between 40% and 60%.
- step (a) and step (b) are carried out without solvent since monomers are liquids and miscible to each other.
- the metal catalytic system of step (a) uses Cu°/Cu 2+ as transition metal, Tris(2-dimethylaminoethyl)amine as ligand, Methyl 2-bromopropionate as initiator, and dimethyl sulfoxide as solvent.
- Step (c) of the process of the invention refers to the preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning.
- step (c) is performed in the presence of an additive capable of increasing the conductivity of the solution blend/solvent. More preferably, in the presence of hydrochloric acid (1HCI), wherein the weight percent of HCI in step (c) is between 0.0001 % and 0.2%.
- HCI hydrochloric acid
- the solvent of step (c) is selected from the list consisting of acetone, dimethyl formamide, polyethylene glycol), dimethyl sulfoxide, 1 -4 Dioxane, ethanol, propanol, hexane, water, carbon dioxide , ionic liquid, and a combination thereof. More preferably, the solvent of step (c) is dimethyl sulfoxide.
- the weight percent of the solvent used in step (c) is ranging between 20% and 98%.
- Step (d) refers to a heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30 e C and 80 e C and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
- the aim of this step (d) is to convert the nanofibers membrane obtained in step (c) from hydrophobic to hydrophilic; a visual transformation of the membrane is observed when wet thermal treatment of step (d) is performed for at least 4 hours. Please note that the membrane lasts hydrophilic for days, even years.
- a third aspect of the invention refers to a process of preparation of the hydrophilic nonwoven nanofibers membrane comprising S1O2 nanoparticles, wherein said S1O2 nanoparticles are homogenously dispersed in the membrane, characterised in that it comprises all steps of the process of the invention:
- step (c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning, and d) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30 e C and 80 e C, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
- step (c) comprises S1O2 nanoparticles.
- Another aspect of the invention refers to a process of preparation of the hydrophilic nonwoven nanofibers membrane comprising S1O2 nanoparticles, wherein said S1O2 nanoparticles are physically adsorbed, characterised in that it comprises all steps of the process of the invention:
- a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) and optionally comprises S1O2 nanoparticles, by electrospinning, and
- step (c) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30 e C and 80 e C, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
- hydrolysed hydrophilic nonwoven nanofibers membrane characterised in that it comprises the hydrophilic nonwoven nanofibers membrane comprising carboxyl groups, wherein the concentration of carboxyl groups in the membrane is ranging between 20 pmol/g of the membrane and 3000 pmol/g of the membrane.
- hydrolysed hydrophilic nonwoven nanofibers membrane refers herein to the hydrophilic nonwoven nanofibers membrane mentioned above which has been partially hydrolysed and now comprises carboxyl groups (COOH) and dried afterwards at room temperature (18-28 e C).
- the number of accessible COOH groups in the membrane is ranging between 20 pmol/g of the membrane and 3000 pmol/g of the membrane. It was found that a hydrolysis time longer than 1 hour, produced a high rigidity in the membranes, making them fragile and brittle.
- said membrane is functionalised with a divalent cation selected from Zn +2 , Ca +2 , Mg +2 and Sr +2 , an antibacterial agent and/or any of the combinations thereof. More preferably, the hydrophilic nonwoven nanofibers membrane is functionalised with Zn +2 , Ca +2 and doxicycline.
- the functionalization of the hydrolysed membrane of the present invention with a divalent cation selected from Zn +2 , Ca +2 , Mg +2 and Sr +2 comprises a step of soaking the hydrolysed with a solution of a divalent cation selected from Zn +2 , Ca +2 , Mg +2 and Sr +2 , and a step of drying at room temperature (18-28 e C).
- the functionalization of the hydrolysed membrane of the present invention with an antibacterial agent comprises a step of soaking the hydrolysed with a solution of an antibacterial agent and a step of drying at room temperature (18-28 e C).
- the concentration of Ca 2+ and Zn 2+ loaded in the membrane as (COO )2 is ranging between 0.0125 pmol/g of the membrane and 1500 pmol/g of the membrane.
- a concentration of Calcium and Zinc higher than 1500 pmol/g of the membrane can be loaded in the hydrolysed hydrophilic nonwoven nanofibers membrane, when all the accessible COOH groups are coordinated.
- the excess of Zn 2+ or Ca 2 is physically adsorbed on the membrane ' s surface in the form of their respective salts (ZnC and CaCh) during the drying of the membrane
- Doxycycline (DOX) was bound non-covalently into membrane by acid-base interactions between amine groups of DOX and carboxyl groups of the membrane as well as by hydrogen bonds between the hydroxyl groups of the membrane.
- DOX Doxycycline
- the concentration of DOX is ranging between 0.01 mg/mg of the membrane and 1 mg/mg of the membrane.
- Another aspect of the invention refers to a non-resorbable membrane for promoting bone regeneration characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above.
- Another aspect of the invention refers to a non-resorbable periodontal membrane characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above.
- Resorbable and non-resorbable barrier membranes are commercially available, being non-resorbable PFTE membranes the Standard of care in Guided Bone Regeneration.
- the main disadvantage of resorbable membranes is the unpredictable resorption time and toxic substances liberated during degradation, affecting bone formation.
- the main disadvantage of non-resorbable barrier membranes is that they do not osseointegrate.
- it is necessary a second surgical intervention to remove them after regeneration that may result in injury of the regenerated tissue. Their poor efficacy results in a high degree of relapse.
- the non-resorbable membrane of the invention is a breakthrough bioactive membrane which allows:
- the last aspect of the invention refers to a coating for an implant characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above which may provide an advantage in osseointegration.
- Osseointegration involves direct contact between for instance titanium implant and bone.
- Most metal transcutaneous implants have failed, primarily owing to infection. Titanium alloy implants produce corrosion particles and fail by mechanisms generally related to surface interaction on bone to promote an inflammation with fibrous aseptic loosening or infection that can require implant removal. Further, lowered oxygen concentrations from poor vasculature at a foreign metal surface interface promote a build-up of host-cell-related electrons as free radicals and proton acid that can encourage infection and inflammation to greatly influence implant failure. Covering the implant with the hydrophilic nonwoven nanofibers membrane mentioned above is an efficient way for avoiding the mentioned risks.
- FIG. 1 Theoretical modelling of co-polymerization of MA and HEA, F a vs conversion (A) and F a vs f a (B).
- FIG. 2 Chromatographic profile of HEA/MA-10/90 (A), HEA/MA-15/85 (B), HEA/MA- 25/75 (C), HEA/MA-35/65 (D), HEA/MA-45/55 (E).
- FIG. 3 FTFIMN spectra of HEA/MA-10/90 (A), HEA/MA-15/85 (B), HEA/MA-25/75 (C), HEA/MA-35/75 (D)
- FIG. 4 Theoretical modelling of co-polymerization of MMA and HEMA, F a vs conversion (A) and F a vs f a (B).
- FIG. 5 Chromatographic profile of MMA-co-HEMA (A), and H 1 RMN spectra of MMA- co-HEMA (B).
- FIG. 6. Electrospinning set up: injection pump (1 ), injection needle (2), Drum collector (3), high voltage sources (4), Taylor cone display (5) and mechanical axis with transversal movement (6).
- FIG. 7 Nonwoven mat produced with the blends: (A)/(B) 0:100 (A), 100:0 (B), 25:75 (C), 50:50 (D), 75:25 (E).
- FIG. 8 Nonwoven mats produced with the blend (A)/(B)75:25 (A), and with the blend (A)/(B)50:50 (B)
- FIG.9. Tiss-OH before (A) and after heating (B).
- FIG.10 Connective collagen network (A), and nonwoven nanofibers mat (Tiss-OH) (B).
- FIG. 11 FESEM micrographs of membranes after 7 days of immersion in SBFS; TissHYD (A), Tiss-Ca 2+ (B), Tiss-Zn 2+ (C).
- FIG. 12 Bone histomorphometry obtained after using Tiss-Zn 2+ , by coloration with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up: histology section including the bone defect and the region of interest (ROI) showing a large formation of dense bone (A).
- FIG. 13 Bone histomorphometry obtained by coloration with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up, after using no membrane- control (A) and Tiss-Ca 2+ (B). Trabecular bone formation were observed along the margin of calvarial defect (arrow head), and within the defect. Mbr: membrane, NB: new bone and OB: old bone (pointers show scattered bone islands, in correspondence with new bone).
- FIG. 14 Bone histology obtained after using Tiss-Zn 2+ (A) and Tiss-Ca 2+ (B) membranes by coloration with toluidine blue to visualize mineralized bone, at six weeks of healing time.
- Single arrows indicate the presence of osteoblasts; double arrows indicate the presence of osteocytes; faced arrows mean blood vessels; pointers indicate fibrous connective tissue.
- NB new bone
- Os osteoid tissue.
- FIG.15 Field Emission scanning electron microscopy (FE-SEM) of F. nucleatum, S. oralis, A. naeslundii, V. parvula, A. actinomycetemcomitans and P. gingivalis grown as multi-species biofilm in vitro at 12 hours of incubation on, PTFE (control) (A), hydroxyapatite (FIAp) discs (B) TissFIYD (C), Tiss-Ca 2+ (D),Tiss-Zn 2+ (E) and Tiss-DOX (F).
- FE-SEM Field Emission scanning electron microscopy
- qPCR quantitative real-time polymerase chain reaction
- Fig.17 FESEM micrographs of tissues after silicon dioxide doping and SBFS immersion for 7 days: Tiss-Si0 2 -COOH (A), Tiss-Si0 2 -Ca 2+ (B), Tiss- Si0 2 -Zn 2+ (C) and Tiss- Si0 -DOX (D).
- MC-LRP Metal Catalysed Living Radical Polymerization
- Cu°-MC-LRP Copper-mediated Living Radical Polymerization
- MA-co-HEA hydrophilic acrylate lineal copolymer with statistical topology and high molecular weight (above 1 x10 6 Da).
- the Cu°-LRP system used was: Methyl 2-bromopropionate as initiator, Tris(2- dimethylaminoethyl)amine as ligand, Copper/Copper(ll) as transition metal: MBP/M 6 - TREN/Cu°/BrCu2, and dimethyl sulfoxide (DMSO) was used as solvent.
- the monomers selected were: methyl acrylate (MA), and hydroxyethyl acrylate (HEA).
- Fig. 1 shows the theoretical modelling of co-polymerization of MA and HEA: F a vs conversion ( F a is the molar fraction of MA in the copolymer along the Polymerization) for different initial molar fractions feed of MA (f 0a ), and F a vs f a (f a is the molar fraction of MA in the feed along the Polymerization).
- Cu°-LRP is very sensitive to any trace of impurities: mainly the inhibitor that contains both monomers, and di-acrylates that are formed in monomer HEA by condensation of HEA molecules.
- impurities mainly the inhibitor that contains both monomers, and di-acrylates that are formed in monomer HEA by condensation of HEA molecules.
- the presence of impurities at very low concentration provides low yields, low molecular weights and crosslinked polymer, and thus it is strictly necessary to properly purify the monomers.
- First HEA was purified in a basic alumina column.
- the required volume of MA was passed through a column of basic alumina.
- (MA-co-HEA)_ copolymers with different molar % of HEA and MA in the feed were synthesised by Cu°-LRP .
- the six different HEA/MA molar % were: a) HEA/MA 10/90 b) HEA/MA 15/85, c) HEA/MA 25/75, d) HEA/MA 34/66, e) HEA/MA 45/55, f) HEA/MA 55/45.
- Table 1 shows the % wt of each component in the final polymerization mixture for each molar % of HEA and MA.
- Table 1 % wt of each component in the mixture for each molar % of HEA and MA.
- the total mass of the monomers (MA + HEA) 59.2700 g was added into 50 ml Schlenk flasks, and then were added: 59.2700 g of DMSO, 0.0020 g of Cu°, 0.0160 g of Tris[2- (dimethylamino)ethyl]amine (M 6 -TREN), 0.0012 g of CuBr 2 , and 0.0060 g of methyl 2- bromopropionate (MBP).
- M 6 -TREN Tris[2- (dimethylamino)ethyl]amine
- MBP methyl 2- bromopropionate
- the sealed flask was placed in a thermostatic oil bath at 25 °C during 24h. Then the copolymers were purified by dissolving in acetone and precipitating them in distilled water (two times). After purification copolymers were dried in a vacuum at 80 e C to a constant weight.
- the copolymers a), b), c), d) had a white colour and rubber texture, and the final conversion was between 90-95%wt in all the cases.
- the co polymerization of e) and f) (Table 1 ) did not occur properly: the yield was below 40%, and the copolymer had not a rubber texture. Therefore the optimal range of molar % of HEA in the feed was between 10% and 34%.
- (MA-co-HEA) copolymers were characterised by GPC (Viscotek 270max of Malvern) and by H 1 RMN (Bruker Avance 400 MHz spectrometer). The samples for GPC were prepared dissolving 1 mg of copolymers in 10 ml 1 -methyl-2-pyrrolidinone (NMP) and they were analysed in triplicate.
- Fig. 2 shows a chromatographic profile of each copolymers, and Table 2 shown the molecular weight ( M w and M n ) and M w /M n .
- Fig. 3 shows the H 1 RMN spectra of said copolymers.
- Table 3 shows the real molar % of HEA in each copolymer: it was calculated by the intensity ratio between the signals a (CH 3 of MA) and b (CH 2 -CH 2 of HEA) of H 1 RMN spectra.
- H 1 RMN The analysis of H 1 RMN shows that the concentrations of HEA in the copolymers are practically the same as the feed concentrations.
- the solubility of synthesised acrylate copolymers was tested in acetone, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 1 -4 dioxane and NMP.
- the copolymers were totally soluble in all the tested solvents up to 6% wt: above 6% the viscosity of the solutions was extremely high.
- the 6% wt solution with lower viscosity was the DMF solution, which indicates that DMF is the best solvent for these copolymers.
- the selected acrylate copolymer for the blend formulations was (MA) 3 -CO-(HEA) 2 (Table 2).
- Fa vs conversion wherein Fa is the molar fraction of MMA in the copolymer along the polymerization for different initial molar fractions feed of MMA ( fo a ), and F a vs 4 wherein 4 is the molar fraction of MMA in the feed along the Polymerization.
- the reverse-ATRP system used was: 2,2'-azobis(2-methylpropionitrile) (AIBN) as initiator, A/,A/,/V,A/",A/"-pentamethyldiethylenetriamine (PMDETA) as ligand, copper(ll) as transition metal, and a mixture of dimethyl sulfoxide (DMSO)/xilene was used as solvent.
- AIBN 2,2'-azobis(2-methylpropionitrile)
- PMDETA A/,A/,/V,A/",A/"-pentamethyldiethylenetriamine
- DMSO dimethyl sulfoxide
- MMA methyl methacrylate
- HEMA 2- hydroxyethylmethacrylate
- the reaction was carried out at 80 °C in an oil bath for 6 hour. After polymerization, the copolymer was purified by dissolving in acetone and precipitating it in distilled water three times. Then the solid copolymer was washing with distilled water 3 times, and dried in a vacuum at 80 e C to a constant weight.
- the methacrylate copolymer had a white colour and a hard and brittle texture. The conversion was 70%.
- MMA-co-HEMA copolymer was characterised by GPC (Viscotek 270 max of Malvern) and by H 1 RMN (Bruker Avance 400 MHz spectrometer). The samples for GPC were prepared dissolving 1 mg of copolymers in 10 ml 1 -Methyl-2-pyrrolidinone (NMP) and they were analysed in triplicate. Fig. 5 shows the chromatographic profile and H 1 RMN spectrum of the prepared MMA-co-HEMA copolymer.
- Table 4 shows molecular weights M w and M n and M w /M n calculated by GPC.
- Table 5 shows the real molar % of HEMA in the copolymer calculated by the intensity ratio between the signals a (CH 3 of MMA) and b (CH 2 -CH 2 of HEMA) of the 1 H-NMR spectra.
- the selected blends; (A)/(B) w/w to be process by electrospinning were: 0/100, 25:75, 50:50, 75:25 and 100/0, and blend/solvent, w/w was 3/97.
- the solutions were loaded into 20 cm 3 teflon syringes (Becton & Dickinson) and extruded through a stainless-steel capillary tube with outer and inner diameters of 1 .5 mm and 1 .1 mm, respectively.
- the injection system was coupled to a mechanical system with axial movement, the flow rates and voltages were selected in order to allow the collection of dry fibers in nonwoven mats, and the fibers were collected on a rotary drum collector.
- Fig. 6 shows the electrospinning set up, and Table 6 shows the electrospinning processing parameters.
- Fig. 7 shows a SEM analysis of nonwoven nanofibers mats obtained with the blends (A)/(B) 0:100 (A), 100:0 (B), 25:75 (C), 50:50 (D), 75:25 (E).
- the copolymer (B) pure provided a very elastic gummy materials, in which the fibers are 100% fused together forming a film (Fig. 7A).
- the blend (A)/(B) 50:50 w/w (from now called Tiss-OH; Fig. 7D) provided a compact nonwoven mats with excellent mechanical properties: very high abrasion resistance, high flexibility, high elasticity, high stress resistance, and thus it is easily to manipulated: can be cut, bend, twist ... etc.
- the optimal solution blend/solvent for scaling the electrospinning process was prepared as follows: 5.000g of (MA) 3 -co-(FIEA)2 (6.246% wt) and 5.000 g of (MMA)i-co- (FIEMA)i (6.246% wt) were dissolve in 70.000g of DMF (87.4479% wt), when the copolymers were completely dissolve, 0.048g of hydrochloric acid (HCI) (0.059% wt) were added to the solution.
- HCI hydrochloric acid
- the electrospinning set up was the same as the one shown in Fig. 6, but in order to increase the production the injection system of a single needle of Fig. 6 was replaced by a ten-needle head.
- Tiss-OH was easily controlled from a few microns to hundreds of microns, by controlling the processing time (2h of processing « 45 pm in thickness).
- Tiss-OH is hydrophobic; to convert it into hydrophilic material is necessary to carry out a further thermal treatment.
- the thermal treatment was done by introducing Tiss-OH, in hot water (40 e C) for 5 hours. To prevent the shrinking of the materials during the thermal treatment, they were kept tensioned using frames.
- the thermal treatment produces an irreversible reorientation of the hydrophobic and hydrophilic domains present on the fibers surface, causing the material to go from being completely hydrophobic to being highly hydrophilic: the OH groups of the fibers are reordered in order to interact by hydrogen bonding with the water molecules, while the hydrophobic groups hide from the water.
- Tiss-OH allowed passing particles from 800nm to 3000nm of diameter.
- the thermal resistance of Tiss-OH was studied by immersing it in water at 100°C during 24h.
- the internal structure, mechanical properties and the mass of Tiss-OH were exactly the same before and after heating (Fig. 9).
- Natural collagen mesh that forms the connective tissue of bones is composed of nanofibrils of approximately 50nm that are grouped to form fibers of approximately 500nm with a similar morphology, mechanical and physical-chemical properties to those of Tiss-OH.
- FIG. 10 SEM pictures of connective collagen network (A) and Tiss-OH (B), that showing the very similar morphological structure.
- the membranes (TissHYD) were washed 3 times with distillated water and dry at room temperature.
- the assay includes the incubation of carboxilated matrixes with toluidine blue O in alkaline buffer with subsequent washing, followed by elution and quantification of eluted TBO via UV-Vis spectrometry.
- the number of accessible carboxyl groups was 560 ⁇ 50 pmol/g of the membrane. After the hydrolysis the Q calculated was 3.06 ⁇ 0.20.
- TissHYD was functionalised with Zn +2 (Tiss-Zn 2+ ) and Ca 2+ (Tiss-Ca 2+ ). The ability of carboxyl groups to complex divalent cations was used to functionalise TissHYD (Tiss- membranes) with Zn +2 and Ca 2+ . TissHYD was soaked with a Zn 2+ and Ca 2+ solution, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYD was loaded with 1 .1 pg/mg, of Ca 2+ and Zn 2+ .
- Doxycycline (DOX) was bound non -covalently into TissHYD by acid-base interactions between amino groups of DOX and carboxyl groups of TissHYD.
- TissHYD was soaked with twice its mass of a DOX solution of 40 mg/ml, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYD was loaded with 0.8 mg of DOX/mg Tiss.
- Membranes should enhance bone formation trough bioactivity, therefore for said application analysis proposed by Kokubo has been performed (ISO 23317:2012. Implants for surgery. In vitro evaluation for apatite-forming ability of implant materials).
- SBFS simulated body fluid solution
- SBFS are fluids with ion concentrations nearly equal to those of human blood plasma and are employed for evaluating the bioactivity of biomaterials for hard tissue repair.
- Zinc complexation on tissues facilitated phosphate groups binding. These phosphate groups, at the surface, have under-coordinated oxygens, which lead to reactive surfaces that will attract calcium ions from SBFS.
- This biomimetic deposition of Ca/P is considered as a coating method inspired by the natural process of biomineralization. Moreover, it should be considered that crystalline HAp is very slow to resorb, and most bone substitutes based on HAp do not resorb or resorb extremely slowly. However, if HAp or nano-HAp is precipitated onto the surfaces, it does resorb, facilitating hard tissue regeneration. Biomimetic remineralization of the tested tissues will facilitate bone regeneration. HAp facilitates formation of other bone apatite-like materials as carbonate HAp and it is able to stimulate cells, leading to the formation of bone. Moreover, HAp promotes osteoconductivity. Osteoblasts stimulated with extracellular Ca 2+ and PO4 2 increased bone morphogenetic protein-2 mRNA expression. Fibroblast growth factor-2 (FGF-2) gene and protein expression levels are also augmented by increases in extracellular Ca 2+ concentration.
- FGF-2 Fibroblast growth factor-2
- the experiment was developed in accordance with the guidelines of the US National Institute of Health (NIH) and European Directive 86/609/EEC regarding the care and use of animals for experimentation.
- the study also complied with the European Directive 2010/63/EU about the protection of animals used for scientific purposes and with all local laws and regulations.
- the researchers obtained the approval of the Ethics Committee of the Institution.
- the minimum number of animals was used for ethical reasons. Comparable models have been published concerning the histological and animal experimentation methods.
- a Prichard periosteotome With a Prichard periosteotome, the epithelial, connective, and muscular tissues were separated from the operation field and the skull surface was washed with a sterile saline solution.
- Six non-critical bone defects (diameter: 6 mm; depth: 3 mm) were created on the parietal bone, on each side of the skull midline, 3 mm apart, using a trephine (Helmut-Zepf Medical Gmbh, Seitingen, Germany) mounted on an implant micromotor operating at 2000 rpm under saline irrigation.
- the trephine had an external diameter of 6 mm, a length of 30 mm, and teeth of 2.35 mm.
- Piezosurgery was used to remove the inner table and the medullary bone in every defect. The depth was controlled with a periodontal probe. A randomly assigned membrane was used to cover each bone defect, leaving a naked defect in each animal. The randomisation sequence was generated using specific software (Research Randomizer, V. 4.0, Urbaniak GC & Pious S, 2013). The membranes were fixed with the fibrin tissue adhesive Tissucol (Baxter, Hyland S.A. Immuno, Rochester, Ml, USA), which was placed on the bone rims adjacent to the defects. Proper adhesion and limited mobility of the membranes were confirmed when the flaps were moved back to their initial positions.
- Sutures were made on the following planes using resorbable material: periosteal (4/0), sub-epidermal (4/0) and skin (2/0). Simple stitches were used as close as possible to the edge.
- the wound was carefully cleaned with a sterile saline solution.
- Anti-inflammatory analgesia (buprenorphine 0.05 mg/kg and carprofen 1 mL/12.5 kg) was administered.
- the animals were sacrificed six weeks after surgery using an intravenous overdose of potassium chloride solution. Samples were obtained from the skull of each specimen, cutting them in an anatomical sagittal plane. After the brain mass was separated and the skull was washed with a sterile saline solution, the tissue samples were cut and marked individually.
- Specimens in cranial blocks were recovered and stored in a 5% formaldehyde solution (pH 7) and blocks were retrieved from the regenerated bone defect using an oscillating autopsy saw (Exakt, Kulzer, Wehrheim, Germany).
- the dissected specimens were immediately immersed in a solution of 4% formaldehyde and 1% calcium and processed for ground sectioning following the Donath and Bruener method.
- For histological staining and rapid contrast tissue analysis Merck Toluidine Blue-Merck, Darmstadt, Germany), a metachromatic dye was used to assess the percentage of new bone formation.
- VK von Kossa
- OS osteoid surface
- OS/TS percentage of osteoid surface
- BPm bone perimeter
- BTh bone thickness
- a 1 % toluidine blue (TB) solution with a pH of 3.6 was chosen and adjusted with HCI 1 N. The samples were exposed to the dye for 10 minutes at RT, rinsed with distilled water, and air-dried. Osteocytes, osteoblasts and blood vessels were analysed in TB stained sections.
- the implanted membranes were well tolerated by the surrounding soft tissues, with no evidence of necrosis, allergy symptoms, immune reactions, or incompatibility. All specimens showed no signs of inflammation or infection induced by the use of biomaterials.
- Fig. 12 shows bone a bone defect with an implanted Tiss-Zn 2+ membrane stained with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up.
- the Fig. 12A is a histology section including the bone defect and the region of interest (ROI), showing a large formation of dense bone.
- the Fig. 12B is the total surface (TS) at ROI; asterisks ( * ) show the presence of marrow and adipose-like tissue. Bony bridging (BB) images are observed. At Fig. 12C, bone perimeter (BPm) at ROI is observed, and in Fig. 12D, bone thickness (BTh) with the traced measurements at ROI is measured.
- an osteoid surface (OS)
- the membranes have higher BTh than control (Ctr), and thus they produced more osteoid surface (OS), in comparison with the control group (see the ratio OS/TS in Tables 9 and 10).
- BS Bone Surface
- OS Osteoid Surface
- TS Total Surface
- BPm Bone Perimeter
- BTh Bone Thickness
- Ctr control.
- Tiss-Zn 2+ achieved higher bone perimeter (BPm) than that produced by TissHYD
- BS Bone Surface
- OS Osteoid Surface
- TS Total Surface
- BPm Bone Perimeter
- BTh Bone Thickness
- Ctr control.
- Fig. 13 For comparison in Fig. 13 are shown bone sections stained by the von Kossa silver nitrate technique at six weeks of follow up, with no membrane -control (Fig. 13A)- and Tiss-Ca 2+ membrane (Fig. 13B). Trabecular bone formation were observed along the margin of calvarial defect (arrow head), and within the defect. The pointers of Fig. 13 (Mbr: membrane, NB: new bone and OB: old bone) show scattered bone islands, in correspondence with new bone. The bone defect in the control group was found to be filled with connective tissue and a few immature bone trabeculae (Fig. 13A). Areas of trabecular bone formation could also be identified in the defects treated with either type of the membrane (Figs. 12B, 13B). Table 11. Bone cells and blood vessels detected within the new bone formed in the region of interest (ROI) (Mean ⁇ Standard Deviation SD).
- ROI region of interest
- Tiss-Zn 2+ and Tiss-Ca 2+ promoted higher number of osteoblasts than the control group.
- the number of osteoblasts was higher in subjects treated with Tiss-Zn 2+ membranes than with unloaded membranes (Table 12). In some fields of all samples, osteoblasts were observed in the process of opposing bone directly on the membrane surface (Figs. 14A and 14B).
- Tiss-Ca 2+ did not produce greater number of osteoblasts than the rest of the membranes but originated higher number of blood vessels than the control group (Table 12).
- Tiss-Ca 2+ showed dense and neat collagen fibers that run parallel to the bone defect and membrane.
- the control group promoted lower amount of blood vessels than Tiss-Ca 2+ .
- Fig. 14A Many large vessels could be detected in samples treated with Tiss-Zn 2+ membranes (Fig. 14A). Small blood vessels were shown in close proximity to the new bone and the Tiss-Ca 2+ biomaterial. Images obtained with TB also permitted to observe that Tiss-Zn 2+ and Tiss-Ca 2+ membranes promoted the formation of bond matrix (Fig. 14) over the membrane, outside the surgical defect. No inflammatory cells or multinuclear giant cells were present at the interface with bone in animals treated with Tiss-Zn 2+ (Fig. 14A).
- BS bone surface
- BTh osteoid and bond thickness
- Tiss-Zn 2+ , Tiss-Ca 2+ and TissHYD membranes induced significant changes in remodeling and structural indices of bone. This increase remodeling might result in the replacement of older, overly mature bone with younger and more resilient bone (Rubin et al., 2018). Osteoid or bone matrix that will be, but not yet, mineralized showed higher surface than in the control group when membranes were used, typical of young bone (La Monaca et al., 2018).
- HAp Hydroxylapatite
- TissHYD Tiss-Ca 2+ (loaded with 1 .1 pg(Ca 2+ )/mg Tiss)
- Tiss-Zn 2+ loaded with 1 .1 pg(Zn 2+ )/mg Tiss
- Tiss-DOX loaded with 0.8 mg(DOX)/mg Tiss. Naked HAp discs and HAp discs covered with a PTFE membrane were used as a control.
- Biofilms from 12 to 72 hours of evolution were observed by Scanning Electron Microscopy (SEM).
- SEM Scanning Electron Microscopy
- the specimens were fixed in a solution at 4% paraformaldehyde and 2.5% glutaraldehyde for 4h at 4 e C. After that, specimens were critical point dried, sputter-coated with gold and analysed.
- the quantitative Polymerase Chain Reaction (qPCR) amplification was performed in a total reaction mixture volume of 10 pL. Analyses were performed with a LightCycler ® 480 II thermocycler (Roche). The plates used in the study was FramStar 480 of natural frame and white wells (4titude; The North Barn; Damphurst Lane, UK), sealed by QPCR Adhesive Clear Seals (4titude). Each DNA sample was analyzed in duplicate. Quantification cycle (Cq) was determined using the provided software package (LC 480 Software 1 .5; Roche). Quantification of cells by qPCR was based on standard curves. The correlation between Cq values and CFU mL -1 were automatically generated through the software (LC 480 Software 1 .5; Roche).
- CFU mL 1 Bacterial counts (CFU mL 1 ) for the six species at 72 h incubation time in the tested specimens are shown in Fig. 16. With time, the dynamics of bacterial growth were similar independent from the specimen. Biofilms on HAp discs coated with Tiss-DOX reached the lowest numbers of bacteria, when is compared with the rest of the groups (p ⁇ 0.01 ).
- Silicon dioxide (S1O2) is able to improve not only bioactivity of materials but also cell adhesion and proliferation on artificial tissues, facilitating osteogenic cells differentiation.
- S1O2 is considered to be osteoinductive and a catalyst for bone formation. Therefore, in order to improve the bioactivity of membranes they were doped with S1O2 nanoparticles (NPs-SiC>2) by two different ways:
- NPS-S1O2 1 g was added to the optimum electrospinning scaling solution (see section 6), and the solution was prepared as follows: 1 .000g of NPS-S1O2 (1 .219 % wt) was dispersed in 70.000 g of DMF (85.316% wt) by 20 min of sonication, then 5.000g of (MA) 5 -co-(HEA) 5 (6.094 % wt), and 6.000 g of (MMA) 3 -co- (HEMA)2 (7.313% wt) were dissolved in the NPS-S1O2/DMF suspension.
- TissHYDSi The ability of carboxyl groups to complex divalent cations was used to functionalise TissHYDSi with Zn +2 and Ca 2+ .
- TissHYDSi was soaked with a Zn 2+ and Ca 2+ solution, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYDSi was loaded with 1 .1 pg/mg, of Ca 2+ and Zn 2+ .
- Doxycycline (DOX) was bound non -covalently into TissHYDSi by acid-base interactions between amine groups of DOX and carboxyl groups of TissHYDSi as well as by hydrogen bonds between the hydroxyl groups of membrane and amine groups of DOX.
- TissHYDSi was soaked with a DOX solution, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYDSi was loaded with 0.8 mg of DOX/mg Tiss.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dentistry (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to a hydrophilic nonwoven nanofiber membrane based on acrylate and methacrylate copolymers and its process of preparation. Furthermore, the invention refers to its hydrolysed form further functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and any of the combinations thereof. Moreover the invention refers to a non-resorbable membrane for promoting bone regeneration and a non-resorbable periodontal membrane comprising said hydrophilic nonwoven nanofiber membrane, its hydrolysed form or its hydrolysed form further functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and any of the combinations thereof.
Description
DESCRIPTION
HYDROPHILIC NONWOVEN NANOFIBERS MEMBRANE FOR PROMOTING BONE
REGENERATION
The invention relates to a hydrophilic nonwoven nanofiber membrane based on acrylate and methacrylate copolymers and its process of preparation. Furthermore, the invention refers to its hydrolysed form further functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and any of the combinations thereof. Moreover, the invention refers to a non-resorbable membrane for promoting bone regeneration and a non-resorbable periodontal membrane comprising said hydrophilic nonwoven nanofiber membrane, its hydrolysed form or its hydrolysed form further functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and any of the combinations thereof.
STATE OF ART
The use of dental implants has become a widespread and predictable treatment modality for the restoration of missing teeth and various edentulous cases. It is clear that the use of a regenerative technique with dental implant placement is an important step which assists the process of bone regeneration. As the clinical success of implant therapy is based on osseointegration, defined as the direct anchorage of the implant in the bone tissue without the interposition of fibrous tissue, considerable research has been conducted to promote bone growth.
The basic principle of Guided Bone Regeneration (GBR) involves the placement of mechanical barriers to protect blood clots and to isolate the bone defect from the surrounding connective tissue, thus providing bone-forming cells with access to a secluded space intended for bone regeneration. GBR has, in many cases, an unpredictable clinical outcome and remains a challenge. Successful bone regeneration requires: I) primary closure of the wound to promote undisturbed and uninterrupted healing, II) angiogenesis to provide necessary blood supply and undifferentiated mesenchymal cells, III) space creation and maintenance to facilitate space for bone in growth and IV) stability of the wound to induce blood clot formation and allow uneventful healing. It is usually obtained by utilization of barrier-membranes that are placed after surgery. There are two types of membranes based on the characteristics of resorbability.
The use of resorbable tissue-engineered matrices to induce bone formation, when additional support is needed, is not always successful. A major limitation of resorbable materials is the inability to exert spatiotemporal control over the wound-healing process. Most of the employed resorbable membranes (e.g. collagen, polylactide-co- glycolide, polycaprolactone) and bone graft substitutes (e.g. hydroxyapatite -HAp- and other calcium phosphates) show a relatively fast rate of biodegradation. It should be taken into account that the healing period of the alveolar bone, after periodontal regeneration or after extraction usually needs 6 to 12 months. Currently, employed resorbable materials may be disadvantageous, as dissolution behaviors are not as long-lasting as required. Moreover, some degradation products from these resorbable materials have low pH, they may not be cytocompatible and could also alter the remineralization processes [Ivanovski S, Vaquette C, Gronthos S, Hutmacher DW, Bartold PM (2014) Multiphasic Scaffolds for Periodontal Tissue Engineering. J Dent Res 93(12):1212-1221 ] [Shimauchi H, Nemoto E, Ishihata H, Shimomura M (2013) Possible functional scaffolds for periodontal regeneration. Japan Dent Sci Rev 49:1 18- 130].
Although much research is being conducted on resorbable periodontal membranes, non-resorbable synthetic membranes of polytetrafluoroethylene (PTFE), still represent the gold-standard for clinicians, due to the higher predictability of their effects when compared to resorbable membranes. However, PTFE possess important disadvantages: I) low adhesiveness for cells, II) total absence of the capability of connecting to the bone tissue and providing osseointegration, without formation of a connective tissue interlayer; then a second surgery is required to remove the non- integrated membrane, and finally III) lack of antibacterial properties, being infections frequently observed [Sam G, Pillai BRM (2014) Evolution of Barrier Membranes in Periodontal Regeneration-Are the third Generation Membranes J of Clin Diagn Res 8: 14-17] Therefore, a successful membrane for GBR should resemble the morphology of natural bone. Natural bone is a hybrid of inorganic-organic tissue composed of hydroxyapatite nanocrystals and collagen fibers (with diameters ranging from 50 to 500nm) assembled into a porous mesh, with interconnected pores. Bone is nanostructured, so nanosized materials should be the best choice for bone substitutes.
For the reasons stated above, it is needed to develop new membranes suitable for bone regeneration.
DESCRIPTION OF THE INVENTION
A first aspect of the present invention relates to a hydrophilic nonwoven nanofibers membrane (herein“the membrane of the invention”) characterised in that it comprises a blend of
o a first copolymer of (MA)3-co-(HEA)2 with statistical topology in a weight percent between 35% and 65%; and
o a second copolymer of (MMA)i-co-(HEMA)i in weight percent between 35% and 65%.
The term“hydrophilic nonwoven nanofibers membrane” refers to a membrane formed by long fibers having a diameter of between 150nm and 400nm. Said membranes are nonwoven, this means that they are like a felt, which are neither woven nor knitted: they are made from long fibers (continuous long), bonded together by chemical, mechanical, heat or solvent treatment, and have a hydrophilic character.
Ideally each needle produces a single fiber that is wound on the drum from the beginning to the end of the electrospinning process (kilometric). The reality is that fibers are cut intermittently along the electrospinning process.
The term“copolymer with statistical topology” refers to statistical copolymers, that is to say, a copolymer in which the distribution of the monomers in the chain is random since all the monomers present in the solution have the same affinity/probability to react both with monomers of the same chemical nature (with themselves) and with monomers of a different chemical nature.
In a preferred embodiment of the membrane of the invention it comprises a blend of
o a first copolymer of (MA)3-co-(HEA)2 with statistical topology in a 50% by weight; and
o a second copolymer of (MMA)i-co-(HEMA)i in a 50% by weight.
Said membrane exhibits abrasion resistance, flexibility, elasticity, stress resistance, and thus it can be easily manipulated: can be cut, bend and twist.
One of the most important parameter in the electrospinning process is the molecular weight of the polymer. Higher molecular weight is generally preferred as there will be greater chains entanglement which facilitates the formation of fibers during spinning. In contrast, lower molecular weight may break up into droplets forming beads or beads combined with short fibers, resulting in heterogeneous materials with unwanted physical properties: irregular surface, low specific surface, low resistance to abrasion, and stress, loss of elasticity.
In another preferred embodiment of the membrane of the invention, the first copolymer of (MA)3-CO-(HEA)2 has molecular weight between 50000 Da and 3-106 Da, preferably above 80000 Da. More preferably, the first copolymer of (MA)3-co-(HEA)2 has molecular weight between 1 106 Da and 3- 106 Da.
In another preferred embodiment of the membrane of the invention, the second copolymer of (MMA)i-co-(HEMA)i has molecular weight between 50000 Da and 1 106 Da.
In another preferred embodiment of the membrane of the invention, the membrane further comprises Si02 nanoparticles (NPs-Si02), and said Si02 nanoparticles are
• homogenously dispersed in the membrane, this is, trapped homogeneously in the whole fiber volume forming a solid solution (composite) and/or
• physically adsorbed on the surface of the membrane,
in a weight percent between 0.1 % and 60% with respect to the final weight of the membrane.
Silicon dioxide (Si02) is able to improve not only bioactivity of materials but also cell adhesion and proliferation on artificial tissues, facilitating osteogenic cells differentiation. Si02 is considered to be osteoinductive and a catalyst for bone formation. Therefore, in order to improve the bioactivity of membranes they were doped with Si02 nanoparticles.
The Si02 nanoparticles (NPs-Si02) can be introduced in the membranes by two ways: 1 ) suspending them in the electrospinning solution, and then carry out the electrospinning process. In this case the NPs-Si02 are trapped homogeneously into the whole fiber volume, forming a solid solution (composite);
2) by physical adsorption in the surface of the fibers once the membrane is made: the membrane is soaked with a suspension of NPS-S1O2, and then the water is evaporated.
The option (1 ) is preferred because NPs-SiC>2 are retained in the fibers more efficiently and its leaching is minimized; by (1 ) the NPs- S1O2 can remain in the membrane for longer times than by (2).
A second aspect of the present invention relates to a process of preparation of the membrane of the present invention (herein“the process of the invention”) that includes the preparation of the copolymers which are electrospun to produce said membrane. The copolymers of the present invention can be prepared by Conventional Free- Radical Polymerization or by Metal-Catalysed Living Radical Polymerization (MC-LRP) such as normal Atom Transfer Radical Polymerization (Normal ATRP), reverse Atom Transfer Radical Polymerization (reverse ATRP) and activator generated by electron transfer atom transfer radical polymerization (AGET ATRP).
In a preferred embodiment of the process of the invention, the process is characterised in that it comprises the following steps:
a) synthesis of the first copolymer of (MA)3-co-(HEA)2 with statistical topology by Metal-catalysed living radical polymerization using a metal catalytic system; b) synthesis of the second copolymer of (MMA)i-co-(HEMA)i by reverse atom transfer radical polymerization using a metal catalytic system;
c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning, and
d) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30 eC and 80 eC, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
Step (a) of the process of the invention refers herein to the synthesis of the first copolymer of (MA)3-co-(HEA)2 by Metal-Catalysed Living Radical Polymerization using a metal catalytic system and step (b) refers to the synthesis of the second copolymer of (MMA)i-co-(HEMA)i by Reverse Atom Transfer Radical Polymerization using a metal catalytic system.
The term “Metal-catalysed living radical polymerization” refers to polymerization methods based on establishing a rapid dynamic equilibration between a minute amount of growing free radicals and a large majority of the dormant species, in which a low oxidation state metal complex acts as the catalyst.
The term“Reverse Atom Transfer Radical Polymerization” refers to the polymerization methods based on establishing a rapid dynamic equilibration between a minute amount of growing free radicals and a large majority of the dormant species, in which a low oxidation state metal complex acts as the catalyst, the dormant species are alkyl halides, and the reaction is initiated by a conventional radical initiator and a Cu" complex.
In the present invention the term“metal catalytic system” refers to the catalyst used in the Metal-Catalysed Living Radical Polymerization of step (a) and to the catalyst used in the reverse Atom Transfer Radical Polymerization of step (b). Said metal catalytic system comprises a metal, a ligand and an initiator and uses a particular solvent. Preferably, the metal catalytic system of step (a) and step (b) is a copper amine complex.
Preferably, the metal of the metal catalytic system of step (a) and/or step (b) comprises a transition metal or a mixture of transition metals in different oxidation states. More preferably, the metal of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of Cu, Fe, Co, Ni, Ru, PI, Rh, Re, Cr and Mo.
Preferably, said metal of the metal catalytic system of step (a) and/or step (b) is in a weight percentage comprised between 0.00001 % and 0.1 %.
Preferably, the ligand of the metal catalytic system of step (a) and/or step (b) is a multidentate aliphatic amine which can be linear or branched. More preferably, the ligand of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of N,N,N',N",N"-Pentamethyldiethylenetriamine (PMDETA) Tris(2-pyridylmethyl)amine, Tris[2-(dimethylamino)ethyl]amine, 2,2'-Bipyridyl, N,N,N',N'- Tetrakis(2-pyridylmethyl)ethylenediamine and 1 ,1 ,4,7,10,10-
Hexamethyltriethylenetetramine. Preferably, said ligand is in a weight percentage between 0.0001 % and 0.2%.
It is to mention that the initiator of step (a) and step (b) are preferably different.
Preferably, the initiator of the metal catalytic system of step (a) is independently selected from the list consisting of Dodecyl 2-bromoisobutyrate, Ethyl a- bromoisobutyrate, Ethyl a-bromoisobutyrate, Octadecyl 2-bromoisobutyrate, Methyl a- bromoisobutyrate, Methyl 3-bromopropionate, tert-Butyl 3-bromopropionate, Ethyl 2- bromopropionate.
Preferably the initiator of step (b) is independently selected from the list consisting of 1 ,Tazobis(cyclohexanecarbonitrile) (ACHN), 2,2’-azobis (2-methylpropionamidine) 2,2’- dihydrochloride (AAPH), 4,4’-azobis(4-cyanovaleric acid) (ACVA), tert-butyl hydroperoxide, cumene hydroperoxide, 2,5-di(tert-butylperoxide)-2,5-dimethyl-3- hexyne, dicumyl peroxide and 2,5-bis(tert-butylperoxide)-2,5-dimethylhexane.
The weight percentage of the initiator in step (a) and step (b) is between 0.00001 % and 0.2%.
Preferably, the solvent used with the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of acetone, dimethyl formamide, polyethylene glycol), dimethyl sulfoxide, 1 -4 Dioxane, ethanol, propanol, hexane, water, carbon dioxide , ionic liquid, and a combination thereof.
The weight percentage of the solvent in step (a) and step (b) is below 90%; preferably the weight percentage of the solvent in step (a) and step (b) is between 40% and 60%.
In another preferred embodiment of the present invention, no solvent is used with the metal catalytic system of step (a) and step (b). In other words, step (a) and step (b) are carried out without solvent since monomers are liquids and miscible to each other.
In a preferred embodiment of the process of the present invention, the metal catalytic system of step (a) uses Cu°/Cu2+ as transition metal, Tris(2-dimethylaminoethyl)amine as ligand, Methyl 2-bromopropionate as initiator, and dimethyl sulfoxide as solvent.
Step (c) of the process of the invention refers to the preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning. Preferably, step (c) is performed in the presence of an additive capable of increasing the conductivity of the solution blend/solvent. More preferably, in the presence of hydrochloric acid (1HCI), wherein the weight percent of HCI in step (c) is between 0.0001 % and 0.2%.
The solvent of step (c) is selected from the list consisting of acetone, dimethyl formamide, polyethylene glycol), dimethyl sulfoxide, 1 -4 Dioxane, ethanol, propanol, hexane, water, carbon dioxide , ionic liquid, and a combination thereof. More preferably, the solvent of step (c) is dimethyl sulfoxide.
Preferably, the weight percent of the solvent used in step (c) is ranging between 20% and 98%.
Step (d) refers to a heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30eC and 80eC and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame. The aim of this step (d) is to convert the nanofibers membrane obtained in step (c) from hydrophobic to hydrophilic; a visual transformation of the membrane is observed when wet thermal treatment of step (d) is performed for at least 4 hours. Please note that the membrane lasts hydrophilic for days, even years.
A third aspect of the invention refers to a process of preparation of the hydrophilic nonwoven nanofibers membrane comprising S1O2 nanoparticles, wherein said S1O2 nanoparticles are homogenously dispersed in the membrane, characterised in that it comprises all steps of the process of the invention:
a) synthesis of the first copolymer of (MA)3-co-(HEA)2 by Metal-Catalysed Living Radical Polymerization using a metal catalytic system;
b) synthesis of the second copolymer of (MMA)i-co-(HEMA)i by Reverse Atom Transfer Radical Polymerization using a metal catalytic system;
c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning, and
d) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30eC and 80eC, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
and wherein the blend of step (c) comprises S1O2 nanoparticles.
Another aspect of the invention refers to a process of preparation of the hydrophilic nonwoven nanofibers membrane comprising S1O2 nanoparticles, wherein said S1O2 nanoparticles are physically adsorbed, characterised in that it comprises all steps of the process of the invention:
a) synthesis of the first copolymer of (MA)3-co-(HEA)2 by Metal-Catalysed Living Radical Polymerization using a metal catalytic system;
b) synthesis of the second copolymer of (MMA)i-co-(HEMA)i by reverse Atom transfer radical polymerization using a metal catalytic system;
c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) and optionally comprises S1O2 nanoparticles, by electrospinning, and
d) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30eC and 80eC, for instance for at least 4 hours, and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
and a further step (e) of soaking the membrane obtained in step (d) in a suspension of NPs- S1O2 and evaporate the solvent.
Another aspect of the invention refers to hydrolysed hydrophilic nonwoven nanofibers membrane (herein the hydrolysed membrane of the present invention) characterised in that it comprises the hydrophilic nonwoven nanofibers membrane comprising carboxyl groups, wherein the concentration of carboxyl groups in the membrane is ranging between 20 pmol/g of the membrane and 3000 pmol/g of the membrane.
The term“hydrolysed hydrophilic nonwoven nanofibers membrane” refers herein to the hydrophilic nonwoven nanofibers membrane mentioned above which has been partially hydrolysed and now comprises carboxyl groups (COOH) and dried afterwards at room
temperature (18-28eC). The number of accessible COOH groups in the membrane is ranging between 20 pmol/g of the membrane and 3000 pmol/g of the membrane. It was found that a hydrolysis time longer than 1 hour, produced a high rigidity in the membranes, making them fragile and brittle.
In a preferred embodiment of the hydrolysed membrane of the present invention, said membrane is functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and/or any of the combinations thereof. More preferably, the hydrophilic nonwoven nanofibers membrane is functionalised with Zn+2, Ca+2 and doxicycline.
The functionalization of the hydrolysed membrane of the present invention with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2 comprises a step of soaking the hydrolysed with a solution of a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, and a step of drying at room temperature (18-28eC).
The functionalization of the hydrolysed membrane of the present invention with an antibacterial agent, more preferably doxycycline, comprises a step of soaking the hydrolysed with a solution of an antibacterial agent and a step of drying at room temperature (18-28eC).
According to the accessible COOH groups in the hydrolysed hydrophilic nonwoven nanofibers membrane, the concentration of Ca2+ and Zn2+ loaded in the membrane as (COO )2 is ranging between 0.0125 pmol/g of the membrane and 1500 pmol/g of the membrane. A concentration of Calcium and Zinc higher than 1500 pmol/g of the membrane can be loaded in the hydrolysed hydrophilic nonwoven nanofibers membrane, when all the accessible COOH groups are coordinated. The excess of Zn2+ or Ca2 is physically adsorbed on the membrane's surface in the form of their respective salts (ZnC and CaCh) during the drying of the membrane
Doxycycline (DOX) was bound non-covalently into membrane by acid-base interactions between amine groups of DOX and carboxyl groups of the membrane as well as by hydrogen bonds between the hydroxyl groups of the membrane. When all the carboxyl and hydroxyl groups available in the membrane are bound to doxycycline, the excess of DOX is physically adsorbed on the membrane’s surface during drying. The
concentration of DOX is ranging between 0.01 mg/mg of the membrane and 1 mg/mg of the membrane.
Another aspect of the invention refers to a non-resorbable membrane for promoting bone regeneration characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above.
Another aspect of the invention refers to a non-resorbable periodontal membrane characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above.
Resorbable and non-resorbable barrier membranes are commercially available, being non-resorbable PFTE membranes the Standard of care in Guided Bone Regeneration. The main disadvantage of resorbable membranes is the unpredictable resorption time and toxic substances liberated during degradation, affecting bone formation. Among many others, the main disadvantage of non-resorbable barrier membranes is that they do not osseointegrate. Moreover, in the case of these latest membranes, it is necessary a second surgical intervention to remove them after regeneration that may result in injury of the regenerated tissue. Their poor efficacy results in a high degree of relapse.
In the present invention the non-resorbable membrane of the invention is a breakthrough bioactive membrane which allows:
• Fully osseointegration, avoiding the need for a second surgery
• Fast bone regeneration through enhancing the precipitation of natural minerals and the activation of bone-forming cells. No need for filling with bone precursors
• Reducing the proliferation of periodontal bacteria when comprises an antibacterial agent
The last aspect of the invention refers to a coating for an implant characterised in that it comprises the hydrophilic nonwoven nanofibers membrane mentioned above which may provide an advantage in osseointegration. Osseointegration involves direct contact between for instance titanium implant and bone. Most metal transcutaneous implants have failed, primarily owing to infection. Titanium alloy implants produce corrosion particles and fail by mechanisms generally related to surface interaction on bone to promote an inflammation with fibrous aseptic loosening or infection that can
require implant removal. Further, lowered oxygen concentrations from poor vasculature at a foreign metal surface interface promote a build-up of host-cell-related electrons as free radicals and proton acid that can encourage infection and inflammation to greatly influence implant failure. Covering the implant with the hydrophilic nonwoven nanofibers membrane mentioned above is an efficient way for avoiding the mentioned risks.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skilled in the art to which this invention belongs. Methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. Throughout the description and claims the word "comprise" and its variations are not intended to exclude other technical features, additives, components, or steps. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples and drawings are provided by way of illustration and are not intended to be limiting of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Theoretical modelling of co-polymerization of MA and HEA, Fa vs conversion (A) and Fa vs fa (B).
FIG. 2. Chromatographic profile of HEA/MA-10/90 (A), HEA/MA-15/85 (B), HEA/MA- 25/75 (C), HEA/MA-35/65 (D), HEA/MA-45/55 (E).
FIG. 3. FTFIMN spectra of HEA/MA-10/90 (A), HEA/MA-15/85 (B), HEA/MA-25/75 (C), HEA/MA-35/75 (D)
FIG. 4. Theoretical modelling of co-polymerization of MMA and HEMA, Fa vs conversion (A) and Fa vs fa (B).
FIG. 5. Chromatographic profile of MMA-co-HEMA (A), and H1RMN spectra of MMA- co-HEMA (B).
FIG. 6. Electrospinning set up: injection pump (1 ), injection needle (2), Drum collector (3), high voltage sources (4), Taylor cone display (5) and mechanical axis with transversal movement (6).
FIG. 7. Nonwoven mat produced with the blends: (A)/(B) 0:100 (A), 100:0 (B), 25:75 (C), 50:50 (D), 75:25 (E).
FIG. 8. Nonwoven mats produced with the blend (A)/(B)75:25 (A), and with the blend (A)/(B)50:50 (B)
FIG.9. Tiss-OH before (A) and after heating (B).
FIG.10. Connective collagen network (A), and nonwoven nanofibers mat (Tiss-OH) (B).
FIG. 11. FESEM micrographs of membranes after 7 days of immersion in SBFS; TissHYD (A), Tiss-Ca2+ (B), Tiss-Zn2+ (C).
FIG. 12. Bone histomorphometry obtained after using Tiss-Zn2+, by coloration with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up: histology section including the bone defect and the region of interest (ROI) showing a large formation of dense bone (A). Total surface (TS) at ROI; asterisks (*) show the presence of marrow and adipose-like tissue (B); bony bridging (BB) images are observed. Bone perimeter (BPm) at ROI (C). Bone thickness (BTh) with the traced measurements at ROI (D). Osteoid surface (OS), ROI (E).
FIG. 13. Bone histomorphometry obtained by coloration with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up, after using no membrane- control (A) and Tiss-Ca2+ (B). Trabecular bone formation were observed along the margin of calvarial defect (arrow head), and within the defect. Mbr: membrane, NB: new bone and OB: old bone (pointers show scattered bone islands, in correspondence with new bone).
FIG. 14. Bone histology obtained after using Tiss-Zn2+ (A) and Tiss-Ca2+ (B) membranes by coloration with toluidine blue to visualize mineralized bone, at six weeks of healing time. Single arrows indicate the presence of osteoblasts; double arrows
indicate the presence of osteocytes; faced arrows mean blood vessels; pointers indicate fibrous connective tissue. NB: new bone, Os: osteoid tissue.
FIG.15. Field Emission scanning electron microscopy (FE-SEM) of F. nucleatum, S. oralis, A. naeslundii, V. parvula, A. actinomycetemcomitans and P. gingivalis grown as multi-species biofilm in vitro at 12 hours of incubation on, PTFE (control) (A), hydroxyapatite (FIAp) discs (B) TissFIYD (C), Tiss-Ca2+ (D),Tiss-Zn2+ (E) and Tiss-DOX (F).
FIG.16. Number of bacteria [Log CFU/biofilm mean (standard deviation)] of F. nucleatum, S. oralis, A. naeslundii, V. parvula, A. actinomycetemcomitans and P. gingivalis grown as multi-species biofilm in vitro at 72 hours of incubation, measured by quantitative real-time polymerase chain reaction (qPCR) (N=3 for each incubation time) in Hydroxyapatite discs (HAp), PTFE (control), T-COOH,Tiss-Ca2+, Tiss-Zn2+ and Tiss- DOX.
Fig.17. FESEM micrographs of tissues after silicon dioxide doping and SBFS immersion for 7 days: Tiss-Si02-COOH (A), Tiss-Si02-Ca2+ (B), Tiss- Si02-Zn2+ (C) and Tiss- Si0 -DOX (D).
EXAMPLES
1. COPOLYMERS SYNTHESIS
1.1 Preparation of (MA-co-HEA) copolymers
In the present invention a variant of Metal Catalysed Living Radical Polymerization (MC-LRP): Copper-mediated Living Radical Polymerization (Cu°-MC-LRP) has been optimised to obtain hydrophilic acrylate lineal (MA-co-HEA) copolymer with statistical topology and high molecular weight (above 1 x106 Da).
The Cu°-LRP system used was: Methyl 2-bromopropionate as initiator, Tris(2- dimethylaminoethyl)amine as ligand, Copper/Copper(ll) as transition metal: MBP/M6- TREN/Cu°/BrCu2, and dimethyl sulfoxide (DMSO) was used as solvent. The monomers selected were: methyl acrylate (MA), and hydroxyethyl acrylate (HEA).
First a theoretical analysis of the co-polymerization of MA and HEA was done by using the terminal model [Mayo, F. R.; Lewis, F. M. J. Am. Chem Soc. 66, (1944), 1594 -
1601]. The terminal model assumes that radical reactivity only depends on the terminal unit of the growing chain, such that the molar fraction of monomer-a in the copolymer (Fa) depends only of monomer mole fractions (fa and fb, with fa + fb, =1) and the monomer reactivity ratios:
F rafa + fafb
rafa + 2 fafb + rbfb where ra and rb are the co-polymerization Reactivity Ratios ra = kpaa/kpab, rb = kpbb/kpba, kpij is the propagation rate coefficient for addition of monomer-y to radical-/. The co polymerization Reactivity Ratios for MA and HEA used are ra=0.94 and rb=0.90 respectively.
Fig. 1 shows the theoretical modelling of co-polymerization of MA and HEA: Fa vs conversion ( Fa is the molar fraction of MA in the copolymer along the Polymerization) for different initial molar fractions feed of MA (f0a), and Fa vs fa (fa is the molar fraction of MA in the feed along the Polymerization).
Theoretical modelling of co-polymerization of MA and HEA shows that Fa is practically equal to the initial molar fraction of feed (Fig. 1A) for any initial molar fractions of MA (Fig. 1 B). The system runs through an almost azeotropic co-polymerization to any initial molar fraction of the feed. Therefore, theoretically the co-polymerization of MA and HAE provide copolymer with statistical topology (MA-HEA-MA-HEA-MA- HEA . ).
Cu°-LRP is very sensitive to any trace of impurities: mainly the inhibitor that contains both monomers, and di-acrylates that are formed in monomer HEA by condensation of HEA molecules. Thus, in Cu°-LRP the presence of impurities at very low concentration provides low yields, low molecular weights and crosslinked polymer, and thus it is strictly necessary to properly purify the monomers.
HEA purification protocol:
1 . First HEA was purified in a basic alumina column.
2. 70 ml of HEA previously purified on basic alumina column, were dissolving in 210 ml of distilled water, and then the traces of ethylene glycol diacrylate were eliminate by 1 1 liquid-liquid extractions with 210 ml of hexane.
3. Then 58 g of NaCI were dissolved in the HEA aqueous solution, and HEA monomer was extracted by 5 liquid-liquid extractions with 200 ml of diethyl ether.
4. The diethyl ether HEA solution was dried whit 300g of anhydrous sodium sulphate: the solution was stirred a few minutes and then was filter to remove the sodium sulphate. .
5. Then the diethyl ether was completely evaporated in a rotavapor, and the purified HEA was stored at -20eC.
MA purification protocol:
1 . The required volume of MA was passed through a column of basic alumina.
Once the monomers were purified, six (MA-co-HEA)_ copolymers with different molar % of HEA and MA in the feed were synthesised by Cu°-LRP . The six different HEA/MA molar % were: a) HEA/MA 10/90 b) HEA/MA 15/85, c) HEA/MA 25/75, d) HEA/MA 34/66, e) HEA/MA 45/55, f) HEA/MA 55/45. Table 1 shows the % wt of each component in the final polymerization mixture for each molar % of HEA and MA.
Table 1. % wt of each component in the mixture for each molar % of HEA and MA.
The total mass of the monomers (MA + HEA) 59.2700 g was added into 50 ml Schlenk flasks, and then were added: 59.2700 g of DMSO, 0.0020 g of Cu°, 0.0160 g of Tris[2- (dimethylamino)ethyl]amine (M6-TREN), 0.0012 g of CuBr2, and 0.0060 g of methyl 2- bromopropionate (MBP).The flasks were closed with a septum, the oxygen was removed by bubbling nitrogen for few minutes, and then four freeze-pump-thaw cycles were done (after the last freeze-pump-thaw cycle the flasks were filled with nitrogen).
Then the sealed flask was placed in a thermostatic oil bath at 25 °C during 24h. Then the copolymers were purified by dissolving in acetone and precipitating them in distilled water (two times). After purification copolymers were dried in a vacuum at 80e C to a constant weight. The copolymers a), b), c), d) had a white colour and rubber texture, and the final conversion was between 90-95%wt in all the cases. The co polymerization of e) and f) (Table 1 ) did not occur properly: the yield was below 40%, and the copolymer had not a rubber texture. Therefore the optimal range of molar % of HEA in the feed was between 10% and 34%. (MA-co-HEA) copolymers were characterised by GPC (Viscotek 270max of Malvern) and by H1RMN (Bruker Avance 400 MHz spectrometer). The samples for GPC were prepared dissolving 1 mg of copolymers in 10 ml 1 -methyl-2-pyrrolidinone (NMP) and they were analysed in triplicate. Fig. 2 shows a chromatographic profile of each copolymers, and Table 2 shown the molecular weight ( Mw and Mn) and Mw/Mn. Fig. 3 shows the H1RMN spectra of said copolymers.
Table 2. Molecular weights of each synthetised copolymer.
Table 3 shows the real molar % of HEA in each copolymer: it was calculated by the intensity ratio between the signals a (CH3 of MA) and b (CH2-CH2 of HEA) of H1RMN spectra.
Table 3. Real molar % of HEA in each synthetised copolymer.
The analysis of H1RMN shows that the concentrations of HEA in the copolymers are practically the same as the feed concentrations.
The solubility of synthesised acrylate copolymers was tested in acetone, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 1 -4 dioxane and NMP. The copolymers were totally soluble in all the tested solvents up to 6% wt: above 6% the viscosity of the solutions was extremely high. The 6% wt solution with lower viscosity was the DMF solution, which indicates that DMF is the best solvent for these copolymers.
In order to have the maximum concentration of functional groups (OH groups) in the nonwoven nanofibers mat, the selected acrylate copolymer for the blend formulations was (MA)3-CO-(HEA)2 (Table 2). 1.2 Preparation of MMA-co-HEMA copolymers
The theoretical modelling of co-polymerization of MMA and HEMA with statistical topology (MMA-HEMA-MMA-HEMA-MMA-HEMA . ) is shown at Fig. 4: Fa vs conversion wherein Fa is the molar fraction of MMA in the copolymer along the polymerization for different initial molar fractions feed of MMA ( foa ), and Fa vs 4 wherein 4 is the molar fraction of MMA in the feed along the Polymerization.
The Cu°-LRP technique used to synthesise the MA-co-HEA copolymers did not work well in the co-polymerization of the methacrylic monomers (MMA and HEMA): very low yields, and molecular weights were obtained, and also the concentration of HEMA in the copolymers was much lower than feed concentrations.
Therefore, in order to synthetised a methacrylate copolymer chemically miscible with (MA)3-CO-(HEA)2, the co-polymerization of MMA and HEMA was carried out by another variant of MC-LRP how is reverse Atom Transfer Radical Polymerization (reverse- ATRP) [Chem. Rev. 101, (2001), 2921-2990.]·. Molecular weight as high as in Cu°-LRP cannot be obtained by reverse ATRP, but reverse-ATRP is much less sensitive to impurities, and thus much easier to carry out.
The reverse-ATRP system used was: 2,2'-azobis(2-methylpropionitrile) (AIBN) as initiator, A/,A/,/V,A/",A/"-pentamethyldiethylenetriamine (PMDETA) as ligand, copper(ll) as transition metal, and a mixture of dimethyl sulfoxide (DMSO)/xilene was used as solvent. The selected monomers were methyl methacrylate (MMA), and 2- hydroxyethylmethacrylate (HEMA).
Protocol of purification of MMA and HEMA:
1 . The required volume of MMA and HEMA was passed through a column of basic alumina.
In a 500ml two-necked flask equipped with a reflux and magnetic stirrer were added: 95.00ml of DMSO, 0.14g CuBr2 0.24g of A/,/V,/V,A/",A/"-pentamethyldiethylenetriamine (PMDETA), 90.08g of MMA and 40.12g of HEMA previously purified, 0.23g of 2,2'- azobis(2-methylpropionitrile) (AIBN) dissolved in 60.02 g of xylene. The mixture was stirred at 250 rpms, when all the components were completely dissolved the reaction mixture was cooled at 0e C and purged with highly pure nitrogen for 20 min. Then the reaction was carried out at 80 °C in an oil bath for 6 hour. After polymerization, the copolymer was purified by dissolving in acetone and precipitating it in distilled water three times. Then the solid copolymer was washing with distilled water 3 times, and dried in a vacuum at 80e C to a constant weight. The methacrylate copolymer had a white colour and a hard and brittle texture. The conversion was 70%.
Weight % of each component in the co-polymerization mixture : 33.200% DMSO, 0.050% CuBr2, 0.083% PMDETA, 14.030% HEMA, 31 .500% MMA, 0.080% AIBN and 21 .000% xylene.
The MMA-co-HEMA copolymer was characterised by GPC (Viscotek 270 max of Malvern) and by H1RMN (Bruker Avance 400 MHz spectrometer). The samples for GPC were prepared dissolving 1 mg of copolymers in 10 ml 1 -Methyl-2-pyrrolidinone (NMP) and they were analysed in triplicate. Fig. 5 shows the chromatographic profile and H1RMN spectrum of the prepared MMA-co-HEMA copolymer.
Table 4 shows molecular weights Mw and Mn and Mw/Mn calculated by GPC.
Table 4. Molecular weights of MMA-co-HEMA copolymers.
Furthermore, Table 5 shows the real molar % of HEMA in the copolymer calculated by the intensity ratio between the signals a (CH3 of MMA) and b (CH2-CH2 of HEMA) of the 1 H-NMR spectra.
Table.5. Real Molar % of HEMA in the copolymers.
The solubility of (MMA)i-co-(HEMA)i was tested in acetone, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 1 -4 dioxane and NMP, and the copolymer was totally soluble up to a percentage of 38% wt; above 38% the viscosity of the solutions was extremely high. For (MMA)i-co-(HEMA)i the 38% wt solution with lower viscosity also was DMF solution, which indicates that DMF is also the best solvent for this copolymer.
2. PREPARATION OF NONWOVEN MAT BY ELECTROSPINNING The solubility between copolymers (MMA)i-co-(HEMA)i ; (A) and (MA)3-co-(HEA)2; (B) was tested in acetone, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1 -4 Dioxane and NMP. The (A)/(B) w/w ratios tested were: 10/90, 25/75, 50/50, 75/25 and 90/10, and the ratio ((A)+(B))/solvent, w/w was 3/97 in all the cases. Both copolymers were completely soluble in all the solvents, at all of ratios. The solutions of lower
viscosity were DMF solutions, and thus DMF was selected as solvent to optimize the electrospinning process.
In order to study and modulate the mechanical properties of nonwoven mats, the selected blends; (A)/(B) w/w to be process by electrospinning were: 0/100, 25:75, 50:50, 75:25 and 100/0, and blend/solvent, w/w was 3/97. When the copolymers were completely dissolved the solutions were loaded into 20 cm3 teflon syringes (Becton & Dickinson) and extruded through a stainless-steel capillary tube with outer and inner diameters of 1 .5 mm and 1 .1 mm, respectively. The injection system was coupled to a mechanical system with axial movement, the flow rates and voltages were selected in order to allow the collection of dry fibers in nonwoven mats, and the fibers were collected on a rotary drum collector. Fig. 6 shows the electrospinning set up, and Table 6 shows the electrospinning processing parameters.
Table 6. Electrospinning processing parameters.
Fig. 7 shows a SEM analysis of nonwoven nanofibers mats obtained with the blends (A)/(B) 0:100 (A), 100:0 (B), 25:75 (C), 50:50 (D), 75:25 (E).
The copolymer (B) pure provided a very elastic gummy materials, in which the fibers are 100% fused together forming a film (Fig. 7A).
The nonwoven mats obtained whit the copolymer (A) pure, did not have any fusion point between fibers, they were completely loose (Fig. 7B), and this provided materials with a null abrasion resistance; hardly manipulable materials.
In the nonwoven mats obtained with the blend (A)/(B) 25:75 (Fig. 7C), the fusion between fibers was no longer 100% as in the case the copolymer (B) pure (Fig. 7A), but there were still many fusion points between fibers (black circles in Fig. 7C), and
thus nonwoven mats with very low specific surface, and very high elasticity were obtained.
The blend (A)/(B) 75:25 (Fig. 7E) provided a compact nonwoven mats with better abrasion resistance than the obtained with the copolymer (A) pure (Fig. 7B), but the mats were not yet flexible, and they showed a very low resistance to stress.
The blend (A)/(B) 50:50 w/w (from now called Tiss-OH; Fig. 7D) provided a compact nonwoven mats with excellent mechanical properties: very high abrasion resistance, high flexibility, high elasticity, high stress resistance, and thus it is easily to manipulated: can be cut, bend, twist ... etc.
The low abrasion resistance of nonwoven mat produced with the blend (A)/(B)75:25, compared with the nonwoven mat produce with blend (A)/(B)50:50 is shown in the Fig. 8.
Electrospinnina scaling process of Tiss-OH
In order to increase Tiss-OH production, the ratio blend/solvent (DMF) w/w was studied. The optimum blend/DMF w/w % was 13.50/86.50: above it the viscosity was too high to be process by electrospinning.
In order to keep the electrospinning process stable over the time, it was necessary to increase the conductivity of the solution blend/solvent by addiction of 0.048g of hydrochloric acid (HCI).
The optimal solution blend/solvent for scaling the electrospinning process was prepared as follows: 5.000g of (MA)3-co-(FIEA)2 (6.246% wt) and 5.000 g of (MMA)i-co- (FIEMA)i (6.246% wt) were dissolve in 70.000g of DMF (87.4479% wt), when the copolymers were completely dissolve, 0.048g of hydrochloric acid (HCI) (0.059% wt) were added to the solution.
The electrospinning set up was the same as the one shown in Fig. 6, but in order to increase the production the injection system of a single needle of Fig. 6 was replaced by a ten-needle head.
The optimized electrospinning parameters for a ten-needle head are shown in the
Table 7.
Table 7. Scaling electrospinning parameter
The thickness of Tiss-OH was easily controlled from a few microns to hundreds of microns, by controlling the processing time (2h of processing « 45 pm in thickness).
2.1. Conversion of Tiss-OH from hydrophobic to hydrophilic Initially Tiss-OH is hydrophobic; to convert it into hydrophilic material is necessary to carry out a further thermal treatment. The thermal treatment was done by introducing Tiss-OH, in hot water (40eC) for 5 hours. To prevent the shrinking of the materials during the thermal treatment, they were kept tensioned using frames.
The thermal treatment produces an irreversible reorientation of the hydrophobic and hydrophilic domains present on the fibers surface, causing the material to go from being completely hydrophobic to being highly hydrophilic: the OH groups of the fibers are reordered in order to interact by hydrogen bonding with the water molecules, while the hydrophobic groups hide from the water.
After thermal treatment the water adsorption capacity (Q) of Tiss-OH, was calculated taking into account the expression:
Q = (Absorbed mass of water) / (Mass of dry nonwoven mat)
Six nonwoven mat samples of different mass were dried in a vacuum oven at 50eC during 2h. Then, they were submerged in distilled water for 3h at room temperature; the water retained in the surface of the samples was removed using a cellulose paper. Subsequently, the samples were weighed and the Q calculated was 2.06 ± 0.15.
Moreover, in order to estimate the pore size distribution of Tiss-OH roughly, a vacuum filtration test using a series of aqueous suspensions of monodisperse hydrophilic nano
and microparticles with sizes between 150nm and 5000nm of diameter has been performed. Tiss-OH allowed passing particles from 800nm to 3000nm of diameter.
The thermal resistance of Tiss-OH, was studied by immersing it in water at 100°C during 24h. The internal structure, mechanical properties and the mass of Tiss-OH were exactly the same before and after heating (Fig. 9).
2.2. Hydrolisis of Tiss-OH to get Tiss-HYD
Natural collagen mesh that forms the connective tissue of bones is composed of nanofibrils of approximately 50nm that are grouped to form fibers of approximately 500nm with a similar morphology, mechanical and physical-chemical properties to those of Tiss-OH.
Fig. 10 SEM pictures of connective collagen network (A) and Tiss-OH (B), that showing the very similar morphological structure.
In order to introduce carboxyl groups (COOH) on the fibers surface, a partial hydrolysis of ester groups: R-COOCH3 and RCOOCH2CH2OH of the membrane Tiss-OH of 45 microns of thickness (Fig. 7D), was carried out to obtain TissHYD. The hydrolysis solution was sodium carbonate (333 mM), pH=12.50. It was found that a hydrolysis time longer than 1 hour, produced a high rigidity in the membranes, making them fragile and brittle. Therefore the time selected for the hydrolysis was 30 min. Therefore the hydrolysis was done by introducing Tiss-OH in a solution of sodium carbonate (333 mM), pH=12.50 during 30 min. Then , the membranes (TissHYD) were washed 3 times with distillated water and dry at room temperature. The number of COOH groups calculated by the toluidine blue O adsorption assay (TBO method) according to Biomaterials.14, (1993), 817-822. The assay includes the incubation of carboxilated matrixes with toluidine blue O in alkaline buffer with subsequent washing, followed by elution and quantification of eluted TBO via UV-Vis spectrometry. The number of accessible carboxyl groups was 560±50 pmol/g of the membrane. After the hydrolysis the Q calculated was 3.06 ± 0.20.
2.2. Functionalization of TissHYD with Zn+2 ( Tiss-Zn 2+) and Ca2+ ( Tiss-Ca 2+)
TissHYD was functionalised with Zn+2 (Tiss-Zn2+) and Ca2+ (Tiss-Ca2+). The ability of carboxyl groups to complex divalent cations was used to functionalise TissHYD (Tiss- membranes) with Zn+2 and Ca2+. TissHYD was soaked with a Zn2+ and Ca2+ solution,
and then the water was evaporated in a vacuum at constant temperature: by this way TissHYD was loaded with 1 .1 pg/mg, of Ca2+ and Zn2+.
2.3. Functionalization of TissHYD with doxycydine (Tiss-DOX)
Doxycycline (DOX) was bound non -covalently into TissHYD by acid-base interactions between amino groups of DOX and carboxyl groups of TissHYD. TissHYD was soaked with twice its mass of a DOX solution of 40 mg/ml, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYD was loaded with 0.8 mg of DOX/mg Tiss.
3. ACELLULAR STATIC IN VITRO BIOACTIVITY TEST OF TissHYD, Tiss-Zn2* Tiss-Ca 2+
Membranes should enhance bone formation trough bioactivity, therefore for said application analysis proposed by Kokubo has been performed (ISO 23317:2012. Implants for surgery. In vitro evaluation for apatite-forming ability of implant materials).
The membranes were soaked in 20 ml of simulated body fluid solution (SBFS) [pH 7.45] in sterile flasks for 7 days. Reagents per 1000 ml of SBFS were: 8.035 g of NaCI, 0.355 g of NaHCOs, 0.225 g of KOI, 0.231 g of K2HR04·3H20, 0.31 1 g of MgCI2-6H20, 39 g of 1 M HCI, 0.292 g of CaCI2, 0.072 g of Na2S04, 1 18 g of Tris, 0 to 5 ml of 1 M HCI for final pH adjustment.
After drying, surfaces were analyzed by FESEM at 2.5 Kv, 3.5 mm working distance and elemental analysis was done by means of an EDX attached to the FESEM, at a working distance of 15 mm. Results from FESEM images of TissHYD, Tiss-Ca2+ and Tiss-Zn2+ after 7 days of immersion in SBFS are presented in Fig. 11.
After immersion, differences between groups were evidenced:
In TissHYD (Fig. 11 A) some rounded deposits were observed rarely on the samples. Traces of calcium were found at the EDX spectra.
In Tiss-Ca2+ (Fig. 11 B), an increase in nanofiber diameter was found, and nanofiber lost their smooth appearance. Spotty calcium deposits were uniformly distributed throughout nanofibers surfaces.
In Tiss-Zn2+ (Fig. 11 C), nanofiber diameter was highly increased (from 300 to about 500nm), and deposits of mineral (100nm) were also randomly distributed onto the nanofibers surfaces.
Calcium and phosphorous were encountered at the EDX spectra on nanofibers surfaces. Numerous agglomerations of spherical nanocrystals were identified onto the Tiss-Zn2+ surface. SBFS are fluids with ion concentrations nearly equal to those of human blood plasma and are employed for evaluating the bioactivity of biomaterials for hard tissue repair. Zinc promoted biomimetic precipitation of Ca/P deposits and formation of Hydroxyapatite (HAp, Caio(P04)6(OH)2) nanocrystals during SBFS immersion. Zinc complexation on tissues facilitated phosphate groups binding. These phosphate groups, at the surface, have under-coordinated oxygens, which lead to reactive surfaces that will attract calcium ions from SBFS. This biomimetic deposition of Ca/P is considered as a coating method inspired by the natural process of biomineralization. Moreover, it should be considered that crystalline HAp is very slow to resorb, and most bone substitutes based on HAp do not resorb or resorb extremely slowly. However, if HAp or nano-HAp is precipitated onto the surfaces, it does resorb, facilitating hard tissue regeneration. Biomimetic remineralization of the tested tissues will facilitate bone regeneration. HAp facilitates formation of other bone apatite-like materials as carbonate HAp and it is able to stimulate cells, leading to the formation of bone. Moreover, HAp promotes osteoconductivity. Osteoblasts stimulated with extracellular Ca2+ and PO42 increased bone morphogenetic protein-2 mRNA expression. Fibroblast growth factor-2 (FGF-2) gene and protein expression levels are also augmented by increases in extracellular Ca2+ concentration.
4. BONE FORMATION IN A RABBIT CALVARIAL DEFECT MODEL
Three types of membranes were tested Tiss-Zn2+ (loaded with 1 .1 pg(Zn2+)/mg Tiss), Tiss-Ca2+ (loaded with 1 .1 pg(Ca2+)/mg Tiss) and TissHYD. Naked defects without any type of membrane were used as a control. Six white, New Zealand-breed experimentation rabbits with identical characteristics (age: 6 months; weight: 3.5-4 kg) were selected for the study and fed daily with rabbit-maintenance Harlan-Teckland Lab Animal Diets (2030). The surgical interventions were carried out at the Minimally Invasive Surgery Centre Jesijs Uson (CCMI, Caceres, Spain). The experiment was developed in accordance with the guidelines of the US National Institute of Health (NIH) and European Directive 86/609/EEC regarding the care and use of animals for experimentation. The study also complied with the European Directive 2010/63/EU about the protection of animals used for scientific purposes and with all local laws and
regulations. The researchers obtained the approval of the Ethics Committee of the Institution. As required by the legislative framework, the minimum number of animals was used for ethical reasons. Comparable models have been published concerning the histological and animal experimentation methods.
Before starting the surgical procedure, vital signs were taken and then immobilisation of the rabbits was carried out. Midazolam (0.25 mg/kg) and propofol (5 mg/kg) were administered intravenously as anaesthetics for induction and an inhalation of 2.8% inspired sevoflurane gas was also used. Analgesia was provided with ketorolac (1 .5 mg/kg) and tramadol (3 mg/kg). Once the animals were sedated and ready, with a No. 15 scalpel blade incisions were made between the bases of their ears and between their eyes. A surgical triangular field was done after connecting the two incisions with another one in the skull midline. With a Prichard periosteotome, the epithelial, connective, and muscular tissues were separated from the operation field and the skull surface was washed with a sterile saline solution. Six non-critical bone defects (diameter: 6 mm; depth: 3 mm) were created on the parietal bone, on each side of the skull midline, 3 mm apart, using a trephine (Helmut-Zepf Medical Gmbh, Seitingen, Germany) mounted on an implant micromotor operating at 2000 rpm under saline irrigation. The trephine had an external diameter of 6 mm, a length of 30 mm, and teeth of 2.35 mm. Piezosurgery was used to remove the inner table and the medullary bone in every defect. The depth was controlled with a periodontal probe. A randomly assigned membrane was used to cover each bone defect, leaving a naked defect in each animal. The randomisation sequence was generated using specific software (Research Randomizer, V. 4.0, Urbaniak GC & Pious S, 2013). The membranes were fixed with the fibrin tissue adhesive Tissucol (Baxter, Hyland S.A. Immuno, Rochester, Ml, USA), which was placed on the bone rims adjacent to the defects. Proper adhesion and limited mobility of the membranes were confirmed when the flaps were moved back to their initial positions. Sutures were made on the following planes using resorbable material: periosteal (4/0), sub-epidermal (4/0) and skin (2/0). Simple stitches were used as close as possible to the edge. The wound was carefully cleaned with a sterile saline solution. Anti-inflammatory analgesia (buprenorphine 0.05 mg/kg and carprofen 1 mL/12.5 kg) was administered. The animals were sacrificed six weeks after surgery using an intravenous overdose of potassium chloride solution. Samples were obtained from the skull of each specimen, cutting them in an anatomical sagittal plane. After the brain mass was separated and the skull was washed with a sterile saline solution, the tissue samples were cut and marked individually.
Specimens in cranial blocks were recovered and stored in a 5% formaldehyde solution (pH 7) and blocks were retrieved from the regenerated bone defect using an oscillating autopsy saw (Exakt, Kulzer, Wehrheim, Germany). The dissected specimens were immediately immersed in a solution of 4% formaldehyde and 1% calcium and processed for ground sectioning following the Donath and Bruener method. For histological staining and rapid contrast tissue analysis (Merck Toluidine Blue-Merck, Darmstadt, Germany), a metachromatic dye was used to assess the percentage of new bone formation. The von Kossa (VK) silver nitrate technique (Sigma-Aldrich Chemical Co., Poole, UK), by using the software Image J, was applied to visualise the mineralised bone. The following data were compiled: bone surface (BS), osteoid surface (OS), percentage of osteoid surface (OS/TS), bone perimeter (BPm) and bone thickness (BTh). A 1 % toluidine blue (TB) solution with a pH of 3.6 was chosen and adjusted with HCI 1 N. The samples were exposed to the dye for 10 minutes at RT, rinsed with distilled water, and air-dried. Osteocytes, osteoblasts and blood vessels were analysed in TB stained sections.
Means and standard deviations (SD) were calculated in pixels, and then converted into mm or mm2. One-way ANOVA and paired samples t-tests were applied with a level of significance at p £ 0.05.
The implanted membranes were well tolerated by the surrounding soft tissues, with no evidence of necrosis, allergy symptoms, immune reactions, or incompatibility. All specimens showed no signs of inflammation or infection induced by the use of biomaterials.
The von Kossa (VK) staining technique permitted to observe that all bone defects treated with membranes showed higher bone surface (BS) and bond thickness (BTh) than the control group (Tables 9 and 10). In the Fig. 12 shows bone a bone defect with an implanted Tiss-Zn2+ membrane stained with von Kossa silver nitrate to visualize mineralized bone, at six weeks of follow up.
The Fig. 12A is a histology section including the bone defect and the region of interest (ROI), showing a large formation of dense bone.
The Fig. 12B is the total surface (TS) at ROI; asterisks (*) show the presence of marrow and adipose-like tissue. Bony bridging (BB) images are observed.
At Fig. 12C, bone perimeter (BPm) at ROI is observed, and in Fig. 12D, bone thickness (BTh) with the traced measurements at ROI is measured.
In the Fig. 12E, an osteoid surface (OS), is represented. It can be appreciated as the membranes have higher BTh than control (Ctr), and thus they produced more osteoid surface (OS), in comparison with the control group (see the ratio OS/TS in Tables 9 and 10).
Table 9. Histomorphometric data obtained within the new bone formed in the region of interest (ROI) (MeaniSD)
Abbreviations: BS: Bone Surface, OS: Osteoid Surface, TS: Total Surface, BPm: Bone Perimeter, BTh: Bone Thickness, Ctr: control.
Tiss-Zn2+ achieved higher bone perimeter (BPm) than that produced by TissHYD
(Table 10).
Table 10. Statistical results of P values after data analysis. Bold letters indicate significance at P < 0.05.
Abbreviations: BS: Bone Surface, OS: Osteoid Surface, TS: Total Surface, BPm: Bone Perimeter, BTh: Bone Thickness, Ctr: control.
For comparison in Fig. 13 are shown bone sections stained by the von Kossa silver nitrate technique at six weeks of follow up, with no membrane -control (Fig. 13A)- and Tiss-Ca2+ membrane (Fig. 13B). Trabecular bone formation were observed along the margin of calvarial defect (arrow head), and within the defect. The pointers of Fig. 13 (Mbr: membrane, NB: new bone and OB: old bone) show scattered bone islands, in
correspondence with new bone. The bone defect in the control group was found to be filled with connective tissue and a few immature bone trabeculae (Fig. 13A). Areas of trabecular bone formation could also be identified in the defects treated with either type of the membrane (Figs. 12B, 13B). Table 11. Bone cells and blood vessels detected within the new bone formed in the region of interest (ROI) (Mean± Standard Deviation SD).
Abbreviations: Ctr: control.
Table 12. Statistical results of P values after data analysis with paired t-tests. Bold letters indicate significance at P < 0.05.
Abbreviations: Ctr: control.
Both Tiss-Zn2+ and Tiss-Ca2+ promoted higher number of osteoblasts than the control group. The number of osteoblasts was higher in subjects treated with Tiss-Zn2+ membranes than with unloaded membranes (Table 12). In some fields of all samples, osteoblasts were observed in the process of opposing bone directly on the membrane surface (Figs. 14A and 14B). Tiss-Ca2+ did not produce greater number of osteoblasts than the rest of the membranes but originated higher number of blood vessels than the control group (Table 12). Tiss-Ca2+ showed dense and neat collagen fibers that run parallel to the bone defect and membrane. The control group promoted lower amount of blood vessels than Tiss-Ca2+. Many large vessels could be detected in samples treated with Tiss-Zn2+ membranes (Fig. 14A). Small blood vessels were shown in close proximity to the new bone and the Tiss-Ca2+ biomaterial.
Images obtained with TB also permitted to observe that Tiss-Zn2+ and Tiss-Ca2+ membranes promoted the formation of bond matrix (Fig. 14) over the membrane, outside the surgical defect. No inflammatory cells or multinuclear giant cells were present at the interface with bone in animals treated with Tiss-Zn2+ (Fig. 14A).
In this experimental study, bone regeneration accounted was observed in all groups. At the end of the study the size of the defects was smaller than its original size. All bone defects showed mineralized bone surface within the region of interest (Fig. 12A), but Tiss-Zn2+, Tiss-Ca2+ and TissHYD attained significantly higher new formed bone (BS) in comparison to controls (Tables 9 and 10). The tissue pattern appeared composed by membranes in close contact to the newly-formed bone and to osteoid tissue. The significantly increase of bone surface (BS), i.e, mineralized bone matrix excluding osteoid and bond thickness (BTh) became associated with a generalized rise of osteoblasts promoted by all membranes when compared with the control group, especially when Tiss-Zn2+ membranes were used (tables 9 and 10). New bone was observed directly in contact with the Tiss-Zn2+ membrane surfaces in the regions displaying successful bone conduction or (Fig. 14A). Newly formed bone was continuous from the defect margin without any invasion of the soft tissue. Continuously regenerated bone adhered to the Tiss-Zn2+ membrane forming bony bridging images (Fig. 14B). Multiple interconnected ossified trabeculae were shown at the region of interest (Fig. 12A).
The Application of Tiss-Zn2+, Tiss-Ca2+ and TissHYD membranes induced significant changes in remodeling and structural indices of bone. This increase remodeling might result in the replacement of older, overly mature bone with younger and more resilient bone (Rubin et al., 2018). Osteoid or bone matrix that will be, but not yet, mineralized showed higher surface than in the control group when membranes were used, typical of young bone (La Monaca et al., 2018).
Not only osteogenesis but enhanced biological activity was also observed after determining the amount of osteoblasts when Tiss-Zn2+ and Tiss-Ca2+ membranes were used (Table 10). Tiss-Zn2+ has been shown to enhance cell proliferation/wound healing (Augustine et al., 2014). Formation of new bone indicates that membranes can induce osteoblasts to fill, or partially fill intracortical pores by nucleating clusters which induce their subsequent fusion to form amorphous calcium phosphate and ultimately apatite crystals, thus reactivating bone-lining cells to bone-forming osteoblasts (Vrahnas et al., 2018). Previous zinc complexation on tissues has been demonstrated to facilitate
phosphate group binding with biomimetic precipitation of Ca/P deposits and formation of hydroxyapatite nanocrystals. These phosphate groups, at the surface, have under coordinated oxygens, which lead to reactive surfaces that will attract calcium ions from the media. This biomimetic deposition of Ca/P is considered as a coating method inspired by the natural process of biomineralization. Even more, phosphoproteins are thought to supply phosphate for mineralization, being capable of modulating crystal nucleation and growth, as well as binding to the collagenous network. Higher solubility of ZnO when in contact with acid substrates, as some acidic non collagenous proteins, could also account for the effective release of zinc ions, which stimulates protein phosphorylation, enhanced calcium deposition, and facilitated crystals precipitation . Osteoblasts stimulated with extracellular Ca2+, and PO4 2 increased bone morphogenetic protein-2 mRNA expression (Shimauchi et al., 2013; Tada et al., 2010). Moreover, the pore connectivity described in these membranes might influence the possibility that a greater number of osteoblasts can penetrate the porous structure (Guarnieri et al., 2018). In addition, an ingrowth of micro vessels was also found nearby the membrane (Fig. 14A) when Tiss-Zn2+ membranes were used, contributing to the integration of the biomaterial in the tissue (Turri and Dahlin, 2015).
Present findings provide further evidence that these membranes act as bioactive modulator for signals communicated to the underlying defects. These results provide evidence that membranes are useful and provide advantageous for bone tissue regeneration.
5. ANTIBACTERIAL EFFECTS OF TlssHYD, Tiss-Zn 2+, Tiss-Ca 2+ AND Tiss-DOX.
Hydroxylapatite (HAp) discs with a 7 mm of diameter and a thickness 1 .8 mm (Clarkson Chromatography Products, Williamsport, PA, USA) were bonded to four types of membranes: TissHYD, Tiss-Ca2+(loaded with 1 .1 pg(Ca2+)/mg Tiss), Tiss-Zn2+ (loaded with 1 .1 pg(Zn2+)/mg Tiss), and Tiss-DOX (loaded with 0.8 mg(DOX)/mg Tiss. Naked HAp discs and HAp discs covered with a PTFE membrane were used as a control. All the specimens were used to develop a multispecies oral biofilm. Reference strains Streptococcus oralis CECT 907T, Veillonella parvula NCTC 1 1810, Actinomyces naeslundii ATCC 19039, Fusobacterium nucleatum DMSZ 20482, Aggregatibacter actinomycetemcomitans DSMZ 8324 and Porphyromonas gingivalis ATCC 33277 were used. In brief, pure cultures of each bacterium were grown anaerobically in a protein-rich medium containing brain-heart infusion. HAp discs control and those covered with the different membranes were then placed in the wells of a 24-well tissue culture plate. Each well was then inoculated with 1 .5 ml. mixed
bacteria suspension prepared, and incubated in anaerobic conditions (10% H2, 10% C02, and balance N2) at 37°C for 12, 24, 48 and 72 h. Plates containing only culture medium will be also incubated to check for sterility.
Biofilms from 12 to 72 hours of evolution were observed by Scanning Electron Microscopy (SEM). For this analysis, the specimens were fixed in a solution at 4% paraformaldehyde and 2.5% glutaraldehyde for 4h at 4eC. After that, specimens were critical point dried, sputter-coated with gold and analysed.
For quantitative evaluation of bacteria growth biofilm DNA, from 12, 24, 48 and 72 hours incubation was isolated using a commercial kit (MolYsis Complete5; Molzym GmgH & CoKG, Bremen, Germany), following manufacturer’s instructions (the protocol for bacterial DNA extraction was followed from step 6, avoiding preliminary steps). The hydrolysis probe 5'nuclease assay PCR method was used for detecting and quantifying the bacterial DNA. Primers and probes were obtained by Life Technologies Invitrogen (Carlsbad, CA, USA), Applied Biosystems (Carlsbad, CA, USA) and Roche (Roche Diagnostic GmbH; Mannheim, Germany) and were targeted against 16S rRNA gene. The quantitative Polymerase Chain Reaction (qPCR) amplification was performed in a total reaction mixture volume of 10 pL. Analyses were performed with a LightCycler® 480 II thermocycler (Roche). The plates used in the study was FramStar 480 of natural frame and white wells (4titude; The North Barn; Damphurst Lane, UK), sealed by QPCR Adhesive Clear Seals (4titude). Each DNA sample was analyzed in duplicate. Quantification cycle (Cq) was determined using the provided software package (LC 480 Software 1 .5; Roche). Quantification of cells by qPCR was based on standard curves. The correlation between Cq values and CFU mL-1 were automatically generated through the software (LC 480 Software 1 .5; Roche).
Shapiro-Wilk goodness-of-fit tests and distribution of data were used to assess normality. Data were expressed as means and Standard Deviation (SD). To compare the effects of the material surface at different exposure times on CFU mL-1, analysis of variance and post-hoc testing with T3 Dunett's correction was used. Results were considered statistically significant at p<0.05.
FESEM images of different biofilms formation are shown in the Fig. 15. After 24 h, high quantities of bacteria were observed on all the discs forming a thick layer of bacteria, with initial characteristics of a structured biofilm. Except for Tiss-Dox discs that showed absent or few isolated bacteria, onto the surfaces. Microbial communities interspersed
with channels could be observed, suggesting that bacteria may have reached the exponential phase of growth. No significant differences among the specimen discs were found in regards to the structure of the biofilm, except with biofilms on Tiss-DOX discs, which lacked an organized structure.
Bacterial counts (CFU mL1) for the six species at 72 h incubation time in the tested specimens are shown in Fig. 16. With time, the dynamics of bacterial growth were similar independent from the specimen. Biofilms on HAp discs coated with Tiss-DOX reached the lowest numbers of bacteria, when is compared with the rest of the groups (p<0.01 ).
6. TissHYD DOPING WITH SI02 NANOPARTICLES (NPS-SIO2)
Silicon dioxide (S1O2) is able to improve not only bioactivity of materials but also cell adhesion and proliferation on artificial tissues, facilitating osteogenic cells differentiation. S1O2 is considered to be osteoinductive and a catalyst for bone formation. Therefore, in order to improve the bioactivity of membranes they were doped with S1O2 nanoparticles (NPs-SiC>2) by two different ways:
1 ) 1 g of NPS-S1O2 was added to the optimum electrospinning scaling solution (see section 6), and the solution was prepared as follows: 1 .000g of NPS-S1O2 (1 .219 % wt) was dispersed in 70.000 g of DMF (85.316% wt) by 20 min of sonication, then 5.000g of (MA)5-co-(HEA)5 (6.094 % wt), and 6.000 g of (MMA)3-co- (HEMA)2 (7.313% wt) were dissolved in the NPS-S1O2/DMF suspension. When the copolymers were completely dissolved, 0.048 g of hydrochloric acid (HCI) (0.058% wt) were added to the solution. Then by using the parameters of the Table 7., the solution was processed by electrospinning, and a nonwoven nanofibers mat doped whit NPS-S1O2 (TissSi-OH) was obtained: The mechanical properties of the membranes were not affected by the incorporation of NPS-S1O2. Then, in order to introduce carboxyl groups (COOH) on the fibers surface, a partial hydrolysis of ester groups: R-COCFI3 and FtCOCPhCPhOH of TissSi-OH was carried out to obtain TissHYDSi. The hydrolysis was done by introducing both membranes in a sodium carbonate (333 mM) pH=12.50 solution during 30min. Then the membranes were washed 3 times with distillated water and dry at room temperature. The number of accessible COOH groups calculated by TBO method was 660±50pmol/g.
2) TissHYD was soaked with a suspension of 10-20nm of S1O2 nanoparticles (S1O2-NPS), and then the water was evaporated in a vacuum at constant
temperature: by this way the membrane was loaded with 0.06 mg of S1O2-NPS /mgTiss.
Then the membranes doped with S1O2-NPS by procedure 1 ) and 2) (TissHYDSi) were functionalize with zinc, calcium and DOX through the following protocols:
6.1. Functionalization of TissHYDSi with Zn+2 ( TissSi-Zn 2+) and Ca2+ ( TissSi-Ca 2+).
The ability of carboxyl groups to complex divalent cations was used to functionalise TissHYDSi with Zn+2 and Ca2+. TissHYDSi was soaked with a Zn2+ and Ca2+ solution, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYDSi was loaded with 1 .1 pg/mg, of Ca2+ and Zn2+.
6.2. Functionalization of TissHYDSi with doxycycline (TissSi-DOX).
Doxycycline (DOX) was bound non -covalently into TissHYDSi by acid-base interactions between amine groups of DOX and carboxyl groups of TissHYDSi as well as by hydrogen bonds between the hydroxyl groups of membrane and amine groups of DOX. TissHYDSi was soaked with a DOX solution, and then the water was evaporated in a vacuum at constant temperature: by this way TissHYDSi was loaded with 0.8 mg of DOX/mg Tiss.
7. ACELLULAR STATIC IN VITRO BIOACTIVITY TEST OF TissHYDSi, TissSi-Zn2* TissSi-Ca2+ AND TissSi-DOX.
To probe for the effect of silicon dioxide inclusion in membranes’ bioactivity, the analysis proposed by Kokubo (ISO 23317:2012. Implants for surgery In vitro evaluation for apatite-forming ability of implant materials) was performed as detailed previously in section number 3.1 .
Results from FESEM images of Tiss-Si02-COOH, Tiss-Si02-Ca2+, Tiss-Si02-Zn2+ and Tiss-Si02-DOX carried out by procedure 1 ) after 7 days of immersion are presented in Fig. 17. Bioactivity of tissues was demonstrated in all cases. The inclusion of silicon dioxide on sample tissues has drastically augmented the appearance of mineral deposits in all tested surfaces (Fig. 11 : without S1O2 and 17: with SiC>2).
Rounded deposits were abundant and uniformly distributed onto nanofibers in all cases: similar results were obtained with the materials doped with S1O2 by the procedure 2).
Si02-doped membranes have shown to increase the bioactivity through an augmented mineralisation.
Claims
1 . A hydrophilic nonwoven nanofibers membrane, characterised in that it comprises a blend of
o a first copolymer of (MA)3-co-(HEA)2 with statistical topology in a weight percent between 35% and 65%; and
o a second copolymer of (MMA)i-co-(HEMA)i in weight percent between 35% and 65%.
2. The hydrophilic nonwoven nanofibers membrane according to claim 1 , characterised in that it comprises a blend of
o a first copolymer of (MA)3-co-(HEA)2 with statistical topology in a 50% by weight; and
o a second copolymer of (MMA)i-co-(HEMA)i in a 50% by weight.
3. The hydrophilic nonwoven nanofibers membrane according to any of claims 1 or 2, characterised in that the first copolymer of (MA)3-co-(HEA)2 has a molecular weight between 50000 Da and 3- 106 Da, preferably above 80000 Da.
4. The hydrophilic nonwoven nanofibers membrane according to claim 3, characterised in that the first copolymer of (MA)3-co-(HEA)2 has molecular weight between 1 106 Da and 3-106 Da.
5. The hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 4, characterised in that the second copolymer of (MMA)i-co-(HEMA)i has molecular weight between 50000 Da and 1 106 Da.
6. The hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 5, characterised in that it further comprises Si02 nanoparticles, wherein said Si02 nanoparticles are homogenously dispersed in the membrane and/or physically adsorbed on the surface of the membrane, in a weight percent between 0.1 % and 60 % with respect to the final weight of the membrane.
7. A process of preparation of the hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 5, characterised in that it comprises the following steps:
a) synthesis of the first copolymer of (MA)3-co-(HEA)2 by Metal-Catalysed Living Radical Polymerization using a metal catalytic system;
b) synthesis of the second copolymer of (MMA)i-co-(HEMA)i by reverse Atom transfer radical polymerization using a metal catalytic system;
c) preparation of a nanofibers membrane comprising a blend, said blend comprising the first copolymer obtained in step (a) and the second copolymer obtained in step (b) by electrospinning, and
d) heat treatment of the nanofibers membrane obtained in step (c), wherein the heat treatment is applied in the form of hot water at a temperature range between 30eC and 80eC and wherein the nanofibers membrane obtained in step (c) is kept tensioned by means of a frame.
8. The process according to claim 7, wherein the metal catalytic system of step (a) and step (b) is a copper amine complex.
9. The process according to claim 7, wherein the metal of the metal catalytic system of step (a) and/or step (b) comprises a transition metal or a mixture of transition metals in different oxidation states.
10. The process according to claim 9, wherein the metal of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of Cu, Fe, Co, Ni, Ru, PI, Rh, Re, Cr and Mo.
1 1 . The process according to any of claims 7, 9 or 10, wherein the ligand of the metal catalytic system of step (a) and/or step (b) is a multidentate aliphatic amine.
12. The process according to any of claims 7, 9 to 1 1 , wherein the ligand of the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of N,N,N',N'',N''-Pentamethyldiethylenetriamine (PMDETA), tris(2- pyridylmethyl)amine, tris[2-(dimethylamino)ethyl]amine, 2,2'-Bipyridyl, N,N,N',N'- tetrakis(2-pyridylmethyl)ethylenediamine and 1 ,1 ,4,7,10,10- hexamethyltriethylenetetramine.
13. The process according to any of claims 7 to 12, wherein the initiator of the metal catalytic system of step (a) is independently selected from the list consisting of dodecyl 2-bromoisobutyrate, ethyl a-bromoisobutyrate, ethyl a-bromoisobutyrate, octadecyl 2-
bromoisobutyrate, methyl a-bromoisobutyrate, methyl 3-bromopropionate, tert-Butyl 3- bromopropionate, ethyl 2-bromopropionate
14. The process according to any of claims 7 to 12, wherein the initiator of the metal catalytic system of step (b) is independently selected from the list consisting of 1 ,Tazobis(cyclohexanecarbonitrile) (ACHN), 2,2’-azobis (2-methylpropionamidine) 2,2’- dihydrochloride (AAPH), 4,4’-azobis(4-cyanovaleric acid) (ACVA), tert-butyl hydroperoxide, cumene hydroperoxide, 2,5-di(tert-butylperoxide)-2,5-dimethyl-3- hexyne, dicumyl peroxide and 2,5-bis(tert-butylperoxide)-2,5-dimethylhexane.
15. The process according to any of claims 6 to 14, wherein the solvent used with the metal catalytic system of step (a) and step (b) is independently selected from the list consisting of acetone, dimethylformamide, polyethylene glycol), dimethyl sulfoxide, 1 , 4-dioxane, ethanol, propanol, hexane, water, carbon dioxide, ionic liquid, and a combination thereof.
16. The process according to any of claims 6 to 14, wherein no solvent is used with the metal catalytic system of step (a) and step (b).
17. The process according to any of claims 6 to 16, wherein the solvent used in step (c) is dimethylformamide.
18. The process according to any of claims 6 to 17, wherein the weight percent of the solvent used in step (c) is ranging between 20% and 98%.
19. A process of preparation of the hydrophilic nonwoven nanofibers membrane according to claim 6, wherein said S1O2 nanoparticles are homogenously dispersed in the membrane, characterised in that it comprises all steps of the process according to any of claims 7 to 18 and wherein the blend of step (c) comprises S1O2 nanoparticles.
20. A process of preparation of the hydrophilic nonwoven nanofibers membrane according to claim 6, wherein said S1O2 nanoparticles are physically adsorbed on the surface of the membrane characterised in that it comprises all steps of the process according to any of claims 7 to 19 and a further step (e) of soaking the membrane obtained in step (d) in a suspension of S1O2 nanoparticles and evaporate the solvent.
21 . A hydrolysed hydrophilic nonwoven nanofibers membrane characterised in that it comprises the hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 6 comprising carboxyl groups, wherein the concentration of carboxyl groups in the membrane is ranging between 20 pmol/g of the membrane and 3000 pmol/g of the membrane.
22. The hydrolysed hydrophilic nonwoven nanofibers membrane according to claim 21 , characterised in that it is functionalised with a divalent cation selected from Zn+2, Ca+2, Mg+2 and Sr+2, an antibacterial agent and/or any of the combinations thereof.
23. The hydrolysed hydrophilic nonwoven nanofibers membrane according to claim 21 , characterised in that the hydrophilic nonwoven nanofibers membrane is functionalised with Zn+2, Ca+2 and doxycycline.
24. A non-resorbable membrane for promoting bone regeneration characterised in that it comprises the hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 6 or the hydrolysed hydrophilic nonwoven nanofibers membrane according to claims 21 to 23.
25. A non-resorbable periodontal membrane characterised in that it comprises the hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 6 or the hydrolysed hydrophilic nonwoven nanofibers membrane according to claims 21 to 23.
26. A coating for an implant characterised in that it comprises the hydrophilic nonwoven nanofibers membrane according to any of claims 1 to 6 or the hydrolysed hydrophilic nonwoven nanofibers membrane according to claims 21 to 23.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201930393 | 2019-05-03 | ||
ES201930393A ES2791771B2 (en) | 2019-05-03 | 2019-05-03 | Hydrophilic nonwoven nanofiber membrane to promote bone regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020224960A1 true WO2020224960A1 (en) | 2020-11-12 |
Family
ID=70465033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/061184 WO2020224960A1 (en) | 2019-05-03 | 2020-04-22 | Hydrophilic nonwoven nanofibers membrane for promoting bone regeneration |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2791771B2 (en) |
WO (1) | WO2020224960A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0569797A2 (en) * | 1992-05-04 | 1993-11-18 | Digestive Care Inc. | Intraoral device for slow medicament release |
WO2015100120A1 (en) * | 2013-12-26 | 2015-07-02 | Tepha, Inc. | Medical implants including laminates of poly-4-hydroxybutyrate and copolymers thereof |
KR20150122444A (en) * | 2014-04-23 | 2015-11-02 | 금오공과대학교 산학협력단 | Surface Modified Nanofibrous GBR membrane and preparation method thereof |
WO2016049682A1 (en) * | 2014-09-29 | 2016-04-07 | Griffith University | Periodontal tissue grafts |
CN107930703A (en) * | 2017-11-27 | 2018-04-20 | 桐乡佳车科技有限公司 | A kind of field controllable anion exchange membrane preparation method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6153210A (en) * | 1997-08-14 | 2000-11-28 | Periodontix, Inc. | Use of locally delivered metal ions for treatment of periodontal disease |
-
2019
- 2019-05-03 ES ES201930393A patent/ES2791771B2/en active Active
-
2020
- 2020-04-22 WO PCT/EP2020/061184 patent/WO2020224960A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0569797A2 (en) * | 1992-05-04 | 1993-11-18 | Digestive Care Inc. | Intraoral device for slow medicament release |
WO2015100120A1 (en) * | 2013-12-26 | 2015-07-02 | Tepha, Inc. | Medical implants including laminates of poly-4-hydroxybutyrate and copolymers thereof |
KR20150122444A (en) * | 2014-04-23 | 2015-11-02 | 금오공과대학교 산학협력단 | Surface Modified Nanofibrous GBR membrane and preparation method thereof |
WO2016049682A1 (en) * | 2014-09-29 | 2016-04-07 | Griffith University | Periodontal tissue grafts |
CN107930703A (en) * | 2017-11-27 | 2018-04-20 | 桐乡佳车科技有限公司 | A kind of field controllable anion exchange membrane preparation method |
Non-Patent Citations (6)
Title |
---|
BIOMATERIALS, vol. 14, 1993, pages 817 - 822 |
CHEM. REV., vol. 101, 2001, pages 2921 - 2990 |
IVANOVSKI SVAQUETTE CGRONTHOS SHUTMACHER DWBARTOLD PM: "Multiphasic Scaffolds for Periodontal Tissue Engineering", J DENT RES, vol. 93, no. 12, 2014, pages 1212 - 1221 |
MAYO, F. R.LEWIS, F. M., J. AM. CHEM SOC., vol. 66, 1944, pages 1594 - 1601 |
SAM GPILLAI BRM, EVOLUTION OF BARRIER MEMBRANES IN PERIODONTAL REGENERATION-ARE THE THIRD GENERATION MEMBRANES J OF CLIN DIAGN RES, vol. 8, 2014, pages 14 - 17 |
SHIMAUCHI HNEMOTO EISHIHATA HSHIMOMURA M: "Possible functional scaffolds for periodontal regeneration", JAPAN DENT SCI REV, vol. 49, 2013, pages 118 - 130 |
Also Published As
Publication number | Publication date |
---|---|
ES2791771B2 (en) | 2021-05-11 |
ES2791771A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Developing a strontium-releasing graphene oxide-/collagen-based organic–inorganic nanobiocomposite for large bone defect regeneration via MAPK signaling pathway | |
Sowmya et al. | Role of nanostructured biopolymers and bioceramics in enamel, dentin and periodontal tissue regeneration | |
Zhao et al. | Bioinspired mineral hydrogels as nanocomposite scaffolds for the promotion of osteogenic marker expression and the induction of bone regeneration in osteoporosis | |
Bao et al. | Effects of electrospun submicron fibers in calcium phosphate cement scaffold on mechanical properties and osteogenic differentiation of umbilical cord stem cells | |
JP5408578B2 (en) | Composition for autologous or allogeneic transplantation using dental pulp stem cells and use thereof | |
Kumar et al. | Synthesis and characterization of diopside particles and their suitability along with chitosan matrix for bone tissue engineering in vitro and in vivo | |
Nie et al. | Nano-hydroxyapatite mineralized silk fibroin porous scaffold for tooth extraction site preservation | |
CN103800946A (en) | Mineralized collagen composite bone adhering and filling material | |
De Olyveira et al. | First otoliths/collagen/bacterial cellulose nanocomposites as a potential scaffold for bone tissue regeneration | |
CN102448504A (en) | Medical devices with galvanic particulates | |
Cañas-Gutiérrez et al. | Bacterial cellulose: a biomaterial with high potential in dental and oral applications | |
Xiang et al. | Sandwich-like nanocomposite electrospun silk fibroin membrane to promote osteogenesis and antibacterial activities | |
Ming et al. | Biomimetic design and fabrication of sericin-hydroxyapatite based membranes with osteogenic activity for periodontal tissue regeneration | |
Soleymani Eil Bakhtiari et al. | Keratin-containing scaffolds for tissue engineering applications: a review | |
Yang et al. | Complexation of injectable biphasic calcium phosphate with phosphoserine-presenting dendrons with enhanced osteoregenerative properties | |
Castillo-Dalí et al. | Pre-prosthetic use of poly (lactic-co-glycolic acid) membranes treated with oxygen plasma and TiO2 nanocomposite particles for guided bone regeneration processes | |
He et al. | Electrospun photocrosslinkable hydrogel fibrous membrane with metal ion trapping capability as an artificial periosteum to promote bone regeneration | |
Chopra et al. | Gelatin nanofibers loaded with zinc-doped hydroxyapatite for osteogenic differentiation of mesenchymal stem cells | |
Wu et al. | Promotion of osteoporotic bone healing by a tannic acid modified strontium-doped biomimetic bone lamella with ROS scavenging capacity and pro-osteogenic effect | |
Li et al. | Elastomeric self-healing antibacterial bioactive nanocomposites scaffolds for treating skull defect | |
Li et al. | Biomimetic Mineralized Hydroxyapatite–Fish-Scale Collagen/Chitosan Nanofibrous Membranes Promote Osteogenesis for Periodontal Tissue Regeneration | |
GB2475468A (en) | Biocompatible materials | |
Pahlevanzadeh et al. | Amorphous magnesium phosphate-graphene oxide nano particles laden 3D-printed chitosan scaffolds with enhanced osteogenic potential and antibacterial properties | |
Chirila | Calcification of synthetic polymers functionalized with negatively ionizable groups: A critical review | |
Suruagy et al. | Physico-chemical and histomorphometric evaluation of zinc-containing hydroxyapatite in rabbits calvaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20721509 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20721509 Country of ref document: EP Kind code of ref document: A1 |